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INTRODUCTION
An early step in the control of gene replication and
expression is exerted through the template functions of
the genome.

Synthesis of RNA, in particular, appears to be

controlled by cell constituents that can repress or enhance
gene expression by associating with specific sites of the
DNA molecule.

Reduction or enhancement of transcription

can also be induced artificially through the introduction
of chemical agents that can interact with and alter the
template capacity of the DNA molecule for nucleic acid
synthesis.

One such agent is ethidium bromide, a drug be-

longing to the family of phenanthridines, compounds
characterized by the presence of a phenanthridinium ring
system in the molecule.

Ethidium bromide is believed to

owe its pharmacological and biological activity, at least
in part, to its ability to reach and bind to the DNA
molecules of the cell .i!J. vivo {Waring, 1972).

l!!. vitro,

ethidium bromide has been shown to bind to DNA as well and
inhibit RNA synthesis as a result of this interaction
{Waring, 1965).

The formation of the DNA-ethidium bromide

complex is accompanied by characteristic changes in the
physicochemical properties of both constituents of the
complex, a fact that has facilitated the study of their
interaction.

As a result, the DNA-ethidium bromide complex

2
has been the subject of numerous studies.

The inhibitory

effectiveness of ethidium bromide against enzymes utilizing
DNA as either substrate or template has also been studied.
Despite considerable accumulation of knowledge
regarding the biological properties of ethidium bromide,
very little is known about the interaction of other phenanthridines with nucleic acids although the pharmacological
activity of many of these structural analogs of ethidium
bromide has been extensively tested.

Very recently the

optical and hydrodynamic properties of some phenanthridineDNA complexes have been studied and were found to be similar
to the properties of the parent compound {Waring, 1974;
Aktipis and Kindelis, 1973a,b).

The inhibitory effective-

ness of these compounds against DNA-dependent DNA polymerase
I and pancreatic deoxyribonuclease I is also comparable with
that of ethidium bromide (Aktipis and Kindelis, 1974).
The subject of the present study is the mechanism of
inhibition of RNA synthesis by structural analogs of ethidium
bromide.

Information pertinent to the factors and parameters

governing RNA synthesis, as well as the mechanism of the
reaction, is presented below.
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1.

The Pharmacological and Biological Properties of
Ethidium Bromide and its Structural Analogs

The pharmacological activity of a large number of
phenanthridines has been extensively investigated.

The

early discovery of antitrypanosomal action (Brownlee et

!J...,

1950) was soon followed by reports on the antibacterial
(Seaman and Woodbine, 1954) and antiviral (Dickinson et

!J...,

1953) activities of these drugs and later on the antileukemic
activity of ethidium bromide on experimental animals (Gosse
~

!l·' 1974).

Apart from its pharmacological action

ethidium bromide has been shown to exert an effect on a
variety of biological functions as well (Waring, 1972).

At

the cellular level ethidium bromide has been found to induce
petite mutation in yeast (Slonimski !!

!J..., 1968) to bind

cooperatively to mitochondrial membranes (Azzi and Santato,
1971) and to eliminate plasmids from the bacterial cytoplasm
(Bouanchaud et

!J..., 1968). At the molecular level ethidium

bromide has been reported to inhibit mitochondrial RNA
synthesis (Zylber and Penman, 1969) and mitochondrial DNA
replication in yeast (Nagley et al., 1973) while, in duck
cells infected by avian sarcoma virus, ethidium bromide
inhibits the appearance of closed circular viral DNA
(Guntake!! !l·' 1975).

The apparent selective inhibition

of exonuclear DNA's by ethidium bromide is thought to reside
in the higher affinity of the drug for supercoiled DNA
molecules (Waring, 1972; Hixon et

!l·•

1975).

4

In vitro studies have revealed that ethidium bromide is
a strong inhibitor of DNA polymerase I {Elliott, 1963; Mayer
and Simpson, 1969), deoxyribonuclease I {Eron and McAuslan,
1966), RNA polymerase {Waring, 1965) and reverse transcriptase
{MUller~

!!·•

1971).

Structural analogs of ethidium bromide examined for
in vitro activity on DNA polymerase I and pancreatic deoxyribonuclease were found to be strong inhibitors of both
enzymes {Aktipis and Kindelis, 1974).
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2.

The

St~ucture

and Properties of the DNA-Drug

Complex
In 1964, Fuller and Waring assigned a tentative
structure to the complex of DNA with ethidium bromide based
on evidence obtained through fiber x-ray diffraction studies
and molecular model building.

In that report, it was

postulated that the planar part of the ethidium bromide
molecule, i.e., the phenanthridinium ring is inserted (Table
1}, in a parallel fashion to the two adjacent base pairs of
double stranded DNA; i.e., present in an intercalation site.
Insertion of the phenanthridinium ring system between
adjacent base pairs was postulated to occur in such a
fashion so as to bring the two amino groups at positions 3
and 8 of the molecule (Table 1} within bonding distance
from the two phosphate groups located opposite each other
on the two DNA strands.

As a consequence, the intercalated

molecule should be stabilized by hydrophobic forces,
including n-n interactions between ethidium bromide and the
neighboring bases. and both hydrogen bonding and electrostatic forces between the amino groups on the drug molecule
and the phosphate groups of the DNA.

In order to accommodate

the intercalated ethidium bromide molecule, the two adjacent
base pairs had to be translocated relative to each other,
resulting in a local unwinding of the double helix.

The

unwinding angle, i.e., the reduction of the 36° helical

6

rotation between two successive base pairs due to the
insertion of one ethidium bromide molecule, was found to
be 12° at the point of intercalation.
The proposed model could account not only for most
of the experimental evidence available at that time, but
also permitted some predictions to be formulated about the
properties of the complex, which have since been substantiated by experiment.

Insertion of the phenthridinium

ring between adjacent base pairs should stabilize the ·double
helix as well as unwind it locally resulting in an overall
length increase of the DNA molecule.

Temperature transition

profiles and electron microscopy in the presence and absence
of ethidium bromide have verified these predictions (Waring,
1966; Freifelder, 1971).

The presence of numerous ethidium

bromide molecules intercalated on the DNA helix has also
been found to cause an increase in the intrinsic viscosity
of the macromolecule that has been attributed to the increase
in the length of DNA (Douthard et !!·, 1973) and a decrease
in the sedimentation coefficient due to the decrease in
the length-specific mass of the complex relative to the
uncomplexed DNA molecule (Douthard et !]_., 1973).

The

sedimentation coefficient of supercoiled double-stranded
circular DNA, on the other hand, is strongly affected by
increasing concentrations of bound ethidium bromide (Crawford
and Warfng, 1967).

This behaviour has been attributed to the

fact that the sedimentation coefficient of supercoiled DNA

•••.
~

~

f
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~olecules

is largely determined by the number of superhelical

turns in the molecule (T).

T is in turn connected with the

ratio of the number of base pairs (N) over the double helix
pitch {p) by the expression:

T

=a

- ~ (Crawford and Waring,

1967) where a is a topological linking number.
constant for any given circular DNA molecule.

a and N are

Therefore,

when the helix pitch is altered by the binding of ethidium
bromide, the number of superhelical turns and the sedimentation coefficient of the superhelical DNA will be affected.
The excellent agreement between extensive theoretical and
experimental considerations of this phenomenon render it the
best piece of evidence in favor of the intercalation model.
In fact, this method is now being used in order to test other
drugs for possible intercalative binding, or in the opposite
sense, in order to test new DNA molecules for circularity
(Waring, 1972).
The optical properties of ethidium bromide show characteristic changes in the visible spectrum when this drug
associates with DNA.

Upon binding to a double-stranded

nucleic acid, the absorption spectrum of ethidium bromide
undergoes a bathochromic and hypochromic shift with the
appearance of two well-defined isosbestic points in the
visible region of the spectrum (Waring, 1965).

Also the

fluorescence quantum yield of ethidium bromide increases
·drastically (Le Pecq and Paoletti, 1967).

The circular

8

dichroism and optical rotatory dispersion spectra of the DNA. ethidium bromide complex show characteristic bands in the
visible region of the spectrum, a consequence of the presence
of the absorbing drug chromophore in an asymmetric environment
(Aktipis and Martz, 1970; Dalgleish et !!·, 1971; Aktipis and
Kindelis, 1973).
The kinetics of formation of the intercalation complex
between ethidium bromide and transfer-RNA have also been
studied.

The results are best fitted by a mechanism in which

ethidium bromide intercalates following a two-step, threecomponent pathway.

In the first step, ethidium bromide and

the DNA (two components) interact to form a complex (the third
component) in which ethidium bromide is bound on the outside
of the DNA helix.

Subsequently, ethidium bromide from this

complex is inserted between the DNA base pairs in a monomolecular, rate-limiting step (Tritton and Mohr, 1971).
Studies on the kinetics of association of ethidium
bromide with double-stranded DNA suggest that in addition to
the above mechanism intercalated ethidium bromide molecules
can also be transferred between intercalation sites in a
direct exchange reaction (Bresloff and Crothers, 1975).
Kinetic experiments of the association of actinomycin D
and proflavine, two other well characterized intercalators,
support the two-step, three-component mechanism as a general
kinetic model for intercalation (Li and Crothers, 1969;
MUller and Crothers, 1968).
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However, some revisions to the original._intercalation
model may be necessary in view of the recent x-ray diffraction
studies on crystalline samples of ethidium bromide doublestranded oligonucleotide complexes (Tsai et

!l.,

1975).

These

studies conclude that the overall geometry of the ethidium
bromide molecule in the intercalation site is in agreement
with the conformation proposed by Fuller and Waring, although
the drug molecule is now placed in the minor groove of the
DNA and the unwinding angle of the helix is found to be 26°
per intercalated drug molecule rather than the 12-14° angle
predicted by the Fuller-Waring model.

Recent hydrodynamic

studies with double-stranded circular DNA have also resulted
in a value of 26° for the unwinding angle (Wang, 1974).
The conformation and the properties of DNA complexes
formed with structural analogs of ethidium bromide have
received very little attention.

The binding parameters of

some of these compounds and ethidium bromide to doublestranded DNA have been found to be of similar magnitude to
one another and the'optical properties of their DNA complexes
share some common features (Kindelis, 1976).
Direct evidence that ethidium bromide analogs also
bind to DNA by intercalation has been obtained with circular
DNA by examining the dependence of the sedimentation coefficient
on the concentration
From these

~f

expe~iments

bound drug as discussed previously.
it was concluded that the ability of

10

the structural analogs of ethidium bromide to bind to DNA by
intercalation is maintained even among compounds carrying
~

extensive substitution on the phenanthridinium ring system
~Wakelin and Waring, 1974).

However, compounds lacking the

amino group at position 8 of the phenanthridinium ring
exhibit characteristic fluorescence and circular dichroism
spectra indicating that the DNA complexes of these analogs
may exist in the intercalation site in conformations
different than those of ethidium bromide and the other.
diamino derivatives (Kindelis, 1976).

11
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3.

The Mechanism of Transcription

RNA synthesis catalyzed by bacterial DNA-dependent
RNA polymerase and viral DNA as template is a multistep
process involving initial binding of the enzyme at nonspecific DNA sites followed by recognition of a specific
..
site, formation of the first phosphodiester bond, elongation
of the product chain and, finally, termination (Burgess !1 !!.,
1969).

With T2 or T4 DNA as template, RNA synthesis may
only be catalyzed by holoenzyme; i.e., core enzyme consisting
of the four stable subunits (a 2ee') plus the less stable cr
subunit (Burgess et !!·' 1969). The cr subunit is necessary
for the enzyme to recognize the correct initiation site on
viral DNA templates (such as T7 , T4 or T2 DNA) and is released
during chain elongation (Travers and Burgess, 1969). Although
the exact mechanism of action of the cr factor is unknown at
the present time it is thought that perhaps it binds to the
core enzyme and may act as an allosteric effector to the
holoenzyme.

Chain elongation with T7 DNA as template yields
in vitro a major RNA product which is approximately 7,000
nucleotides long (Millette et

!l·, 1970), while with T2 or

T4 DNA the average chain length is approximately 5,000
nucleotides (Richardson, 1970; Maitra and Barash, 1969).
rate of chain growh

~vivo

The

is comparable to the rate of

growth in vitro, which with T7 DNA has a value of 36 n~cleo
tides per sec while with T4 DNA this figure is only 22

12

nucleotides per sec (Bremer, 1970).

Since the growth rate

of RNA chains with T2 DNA as template is slower than with
T DNA while the length of the transcript with either template
7
is of comparable size, termination of chain elongation should
not occur within 90 sec of assay time with T2 DNA as template.
The growth rate with T2 DNA which is used in this work would
be expected to be comparable to that of T4 DNA, since the two
molecules have been shown to possess similar chemical,
biological and genetic properties (see for example
1965).

Rau~h,

Although completion of a long transcript in vitro

requires approximately 2 min, addition of one nucleotide to a
growing chain requires only a small fraction of a second.
This rate is very fast compared with the time required for
half the enzyme to locate the initiation sites, which is
15-20 sec (Hinkle and Chamberlin, 1972).

Despite the fact that the values of the kinetic parameters governing the various steps of RNA synthesis have
been determined repeatedly in many laboratories, common
agreement on their exact magnitude is difficult to achieve.
Due to the complexity of the reaction, these kinetic parameters are influenced by a great number of factors, such
.
as temperature, KCl concentrat1on,
Mg ++ and/or Mn ++ concen-

tration, the concentration of template relative to enzyme,
the nature of the template, the a-subunit content pf the
enzyme preparation, the nucleotide substrate concentration,
the sequence of addition of the various components in the

r
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assay mixture, the

pre~incubatton

and incubation time, the

method of collecting the product, to name only a few.· Some
of these factors are bound to vary from one set of conditions
to another, making direct comparison of literature values
very difficult.
Even a brief review_ of the ways in which these factors
might influence the process of RNA synthesis becomes a nearly
impossible task and, for most purposes, a meaningless one.
Because of the enormous complexity of the system catalyzing
this reaction, many factors which might facilitate the rate
of one step might be deleterious to another.

To give only

one example, raising the salt concentration from 0.05 M to 0.2 M
increases the rate of elongation, whereas, it decreases the
number of RNA chains that can be initiated.

At the same time,

RNA polymerase molecules which complete the synthesis of one
chain are released from the template and are able to reinitiate
a new chain in 0.2 M KCl, but only to a smaller extent in
0.05 M KCl (Bremer, 1970).

What are, then, the optimal salt

conditions for RNA synthesis?

The answer to this question is,

naturally, that the effect of each factor should be examined
separately for each step.

Then, the importance of techniques

which would be able to isolate the events of each particular
step becomes evident.
One method for studying the events of RNA chain initiation and chain elongation independently but simultaneously has

14
been described by Maitra and Hurwitz (1965).

This method

relies on the fact that, among all the ribonucleotides to
be incorporated into the RNA product, only the first one
will maintain its

e

andy phosphate groups intact.

One

could, therefore, use a nucleoside triphosphate substrate
labelled on the terminal phosphate with 32 P and on the
purine or pyrimidine ring with 3H or 14 c. Incorporation of
32 P in the product would then be a measure of the number of
chains initiated with that particular nucleotide, while
incorporation of 3 H {or 14 c) would be a measure of the overall rate of RNA synthesis. The ratio of 3H over 32 P would
be a measure of the length of the product chain.

Using

this method, it was found that the large majority {> 90%)
of all product chains are initiated with either an ATP or
GTP as the first nucleotide.

The ratio of chains initiating

with ATP over those initiating with GTP was found to be a
function of many factors and varied between 6/l and 1/1
with intact T4 DNA as template {Maitra et al., 1967).
Denaturation of the DNA or reduced content of a-factor for
the enzyme increased the number of chains initiating with
GTP.

An excellent review article covering the information

available on RNA synthesis prior to 1974 has recently been
published {Chamberlin, 1974).
In 1974, new methods were developed allowing further
resolution of the events that take place during chain
initiation {Mangel and Chamberlin, 1974a; b; c).

This

15

achievement was

accom~lished

by exploiting the property-of

the drug rifampicin to attack and inactivate RNA polymerase
molecules at greatly different rates, depending upon
whether these enzyme molecules are going through initiation,
elongation or are free in solution.

Template-bound RNA

polymerase molecules are inactivated approximately 100 times
slower than free enzyme molecules while elongating polymerase
molecules are truly resistant to rifampicin.

The second

order rate constant of rifampicin attack on holoenzyme-T 7
DNA complex is 3.5 x 10 3 M-l s- 1 (Hinkle et !!·• 1972).
Mangel and Chamberlin formed complexes of

I· coli RNA

polymerase with bacteriophage T7 DNA at 37°C in the absence
of ribonucleotide substrates. Then, the reaction was
initiated by the addition of a mixture of the four ribonucleotides with rifampicin and was allowed to proceed for
90 sec.

In this period of time, the enzyme-DNA binary

complex (RS) can have one of two fates:

a) it may be

inactivated by rifampicin; or b) it may react with a nucleotide and form a ternary initiation complex (OP} which is
resistant to rifampicin and forms product uninhibited.

If

this scheme is correct, Mangel and Chamberlin argue, the
ratio of the rate of the reaction in the absence of
rifampicin over the rate of the reaction in its presence
plotted as a function of increasing rifampicin concentrations should be a straight line of characteristic slope and
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jntercept:
m~~sure

The intercept on the rate axis should be a

of the number of RNA polymerase molecules which

are able to escape rifampicin and form product, while the
slope should be equal to the ratio of the second-order
rate constant of rifampicin attack on the binary enzymeDNA complex (RS), over the rate constant of the transformation of the RS complex to the rifampicin-resistant ternary
complex (OP).

Experiments conducted under a variety of

nucleotide concentrations verified these predictions -and
allowed the calculation of a value of 5 s- 1 for the pseudofirst order rate constant governing the transformation of
the RS to the OP complex with T7 DNA at 0.4 mM XTP (Mangel
and Chamberlin, 1974).
However, the results of similar experiments, conducted
under various temperature and ionic strength conditions,
indicated that another state (I) might exist for the enzymeDNA binary complex, from which the enzyme could rapidly
equilibrate with the RS complex.

Formation of the I complex

is favored over the RS complex at low
and high

(>

(<

10°C) temperature

0.1 M KCl) salt concentrations (Mangel and

Chamberlin, 1974b; c).

In order to measure the rate of

transformatjon of the I to the RS complex, I complexes were
formed by incubating E. coli RNA polymerase and T7 DNA at
ooc under low salt (< 0.05 M KCl) conditions. Subsequently,
the mixtures were transferred into a 37°C bath for increasing
periods of time (pre-incubation).

RNA synthesis was then

17

initiated by the addition of a mixture of rifampicin and
the four ribonucleotide substrates and terminated 90 sec
later.

With increasing pre-incubation time, an increasing

fraction of RNA polymerase molecules would find the necessary
time and be transformed from the I to the RS complex.

Then,

the fraction of enzyme molecules still at I complexes would
be inactivated by rifampicin upon addition of the rifampicinnucleotide mixture, while the majority of the RS complexes
would be able to initiate an RNA chain.

It was indeed

shown that the rate of rifampicin attack on I complexes is
much faster than the rate of transformation of I to RS
(Chamberlin and Ring, unpublished observations, cited by
Chamberlin, 1974).

Consequently, Mangel and Chamberlin

argued and demonstrated experimentally a plot of the rate
of the reaction as a function of pre-incubation time must
yield an exponential curve having a slope equal to the
first order rate constant of the transformation of the I
to the RS complex.

The half-life time of this transforma-

tion was found to be approximately 22 sec under the
conditions of their assay.
Based on the evidence obtained with these methods,
Mangel and Chamberlin postulated that at least two steps
may be distinguished in the process of RNA chain initiation
between the time the initial binding_ of the enzyme at the
specific recognition site on the DNA template takes place
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and the subsequent formation of the first phosphodiester
bond (Scheme I).

In the.first initiation step, an enzyme

molecule already bound on a specific DNA recognition site
in a highly stable rifampicin-sensitive binary complex
(I) transforms into a rapidly-starting (RS) complex.

This

transformation occurs via a temperature dependent, ratelimiting transition that may involve partial unwinding of
the DNA helix as well as translocation of the enzyme along
the template.

In the second initiation step the binary

(RS) complex forms a rifampicin-resistant ternary initiation complex (OP) by forming the first phosphodiester bond.
This latter step does not seem to involve translocation of
the enzyme along the template (Heyden et

!l·•

1975).

The methodology of Mangel and Chamberlin was described
in some detail here not only because of its significance but
also because it is being used in this work in order to study
the effect of various inhibitors of RNA synthesis on each
initiation step.
Application of one of these methods had already
allowed direct measurement of the effect of the number of
superhelical turns of a closed circular DNA on the second
initiation step.

It turns out that superhelicity does not

have any significant effect on the second initiation step
(Richardson, 1975).

On the other hand, the presence of

superhelical turns on the molecule appears to greatly
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s~heme

I.

The mechanism of RNA synthesis.

represents a hypothetical

tem~late

discs an RNA polymerase molecule.

The line

molecule and the dark
For schematic purposes,

different DNA sites have been assigned to each complex
and are

depict~d

either in the "closed,"

---1- - - ;

or in

the "open," ----•---, configuration.

NS

I

RS

.41---------------~

OP

EL

~-----------41t-Description

NS

Non-specific binding - formation of non-specific
complex NS

I

Recognition - formation of the I complex

RS

First initiation step - formation of the RS complex DNA strand separation

OP

Second initiation step - formation of the first
phnsphodiester bond, ternary OP complex

EL

Elongation steps - formation of the elongation
complexes EL
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facilitate the temperature dependent transition through
step 1 {Hayashi and Hayashi, 1971).

However, it is not

known whether superhelicity affects the number or the rate
of enzyme molecules going through the first initiation step.
These recent advances in the understanding of the
mechanism of RNA synthesis

~vitro

have provided clues as

to the possible mode of action of the various transcriptional
control elements

~

vivo.

For instance, one type of a DNA-

binding protein {the CAP protein) has been

identifie~

which facilitates the initiation of transcription in vivo.
Binding of the CAP protein to the DNA induces a structural
transition of the template which may facilitate the formation
of the {RS) complex (Dickson et

!l·•

1975).
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4.

The Mechanism of Inhibition of RNA Synthesis
Through Template Inactivation

Chemical agents that attack and permanently modify
the primary and/or the secondary structure of the DNA are
known to interfere with the template properties of the
macromolecule (Waring, 1972; BUcher and Sie, 1969).

Inhi-

bition of RNA synthesis, however, may also result from
the interaction of the DNA molecule with compounds that
bind reversibly and alter the conformation of the double
helix only for that period of time during which they
remain associated with the template.

For example, com-

pounds that bind to DNA by intercalation between base
pairs like ethidium bromide, proflavine or actinomycin D,
are strong but reversible inhibitors of RNA synthesis.
These compounds however exert their inhibitory effect on
RNA polymerase through various modes of action.

Specifically,

although ethidium bromide, proflavine and actinomycin D all
inhibit the overall rate of RNA syrithesis, each one of
these compounds does so by affecting different steps of the
overall reaction.

Actinomycin D up to a given concentration

interferes only with RNA chain elongation (Sentenac et

!!·•

1968; Hyman and Davidson, 1970) while ethidium bromide
affects almost exclusively chain initiation (Richardson,
1973a).

Proflavine has been found to inhibit both steps
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and to approximately the same extent (Hurwitz et _ti., 1962;
1967; Richardson, 1966a and b).
Ethidium bromide has been the best studied initiation
inhibitor to date.

The activity of this compound as an

inhibitor of RNA synthesis has been found to vary with the
type of template employed and this variation does not appear
to result from the small differences noted in the affinity
of this compound for each different DNA template {Richardson,
1973b).
Binding of ethidium bromide on the DNA-template at
concentrations causing total inhibition of RNA synthesis
does not appear to interfere with the binding of RNA polyerase at non-specific sites on the template {Richardson,
1973a).

On the other hand, ethidium bromide has been found

to inhibit the formation of the strong complexes of RNA
polymerase with specific sites of the template, as
evidenced by the decrease in the amount of complexes

w~ich

are retained on a cellulose nitrate filter in the presence
of inhibitor (Richardson, 1973a).

This inhibition of the

strong binding of RNA polymerase by ethidium bromide
appears to result from the inability of the enzyme to form
complexes with the specific sites of the template in,the
presence of ethidium bromide molecules intercalated in the
vicinity of those sites.

RNA polymerase, however, has the

ability to displace ethidium bromide from its strong
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binding sites while ethidturn bromide, which has a much
weaker affinity for the template than the enzyme, is
unable to induce dissociation of the enzyme from its
strong (cellulose nitrate non-filterable) complexes
(Richardson, 1973a).
However, no quantitative correlation has been
attempted between the degree to which specific binding
of the polymerase to the template is inhibited and the
inhibition of RNA chain initiation (Richardson, 1973a).
Moreover, it is not known which one of the specific
enzyme-DNA complexes described in the previous section
(Scheme I) is inhibited by the template-bound form of
the drug.

Neither is it known whether ethidium bromide

inhibits by causing a reduction in the rate of formation
of specific enzyme-DNA complexes or by causing a decrease
in the number of such complexes that can be formed in the
presence of this inhibitor (or perhaps, by a combination
of the above two modes of inhibition).
A study of the effects of ethidium bromide and some
of its structural analogs on the number and the rate of RNA
polymerase molecules involved in product formation has
been the main goal of this investigation.

Since at least

five individual steps are presently recognized in RNA
synthesis (Scheme I) the effect of each inhibitor on the
number and the rate of RNA polymerase molecules traversing
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each one of these steps has separately been studied.

The

results indicate that ethidium bromide and its structural
analogs inhibit RNA synthesis as a result of their presence
in the vicinity of a specific DNA site which must be
recognized by RNA polymerase in order for the first
productive enzyme-DNA complex to be formed.
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MATERIALS AND METHODS
Nucleoside triphosphates (sodium salts) were purchased
either from Sigma or from P-l Biochemicals specified as at
least 98% pure. Tritium or 32 P-labelled nucleotides were
purchased either as freeze-dried

~mmonium

ethanolic solutions (Amersham-Searle}.

salts or as 50%

In the latter case,

the ethanol was blown off under a stream of nitrogen before
use. Both tritium and 32 P-labelled nucleotides were
purchased at a specific activity of more than 15 Ci/mmol and
were diluted to the desired specific activity with unlabelled
material.

Calf thymus DNA was purchased from Worthington

Biochemical Corporation.

Bacteriophage T2 was obtained
from Miles laboratories at a concentration of 5-10 x 10 12
virus particles per ml and a titer of 2.1 x 10 12 plaque
forming units per ml.
1.

I 2 DNA Preparation

The method described by Bautz and Dunn (1971) was
used for the isolation of T2 DNA.
Six milliliters of the commercial virus suspension
was dialyzed against 2.0 1 of 0.1 M sodium phosphate buffer
pH 7.2 for ·three hours.

The dialyzate was transferred to

a 15 ml conical glass tube and 0.11 volume (0.66 ml) of a
freshly prepared 10% sodium dodecyl sulfate solution was
added.

The mixture was

bro~ght

to 65°C for 3 min, th•n
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rapidly chilled in ice and 1.0 M KCl was added to the
solution to make it 0.3 M in KCl.

After 15 min centrifuga-

tion in the cold (IEC SB206 rotor, 27,000 g), an equal
volume of freshly distilled phenol (saturated with 0.1 M
sodium phosphate buffer pH 7.2 and containing 0.08%

a-

hydroxyquinoline} was added to the supernatant and the
mixture was rocked for 14 min at a frequency of 40 rpm/min.
Centrifugation for 15 min in an IEC clinical, swinging
bucket centrifuge at top speed separated the phenol layer
{yellow) which was discarded with the help of a Pasteur
pipette, from the buffer layer which was dialyzed against
4.0 1 0.01 M Tris-HCl, 0.01 M KCl, 0.00005 M EDTA pH 7.9
with three changes for four days.

The purified T2 DNA
solution was stored at -20°C in five 2 ml aliquots. The

concentration of the product (0.0010 M in nucleotide) was
determined spectrophotometrically assuming a molar extinction
coefficient of 6500 at 260 nm and a nucleotide mean molecular
weight of 357

(Rubenstein~

!l·, 1961).

The A2601280 ratio
of the product was 1.80 and the A2601230 ratio was 2.1,
indicating very low protein contamination (Thomas and

Abelson, 1966).
2.

The Enzyme

Escherichia coli K-12 DNA-dependent RNA polymerase
(EC 2.7.7.6) was purchased from Sigma Chemical Co. as a
50% glycerol solution having a specific activity of ·396
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units per mg protein (2.1 mg protein/ml of solution) using
the unit definition of Burgess (1969) with calf-thymus DNA
as template.

Enzymatic activity assays carried out in the

laboratory under identical conditions yielded a value of

BOO units per ml of solution with calf-thymus DNA as
template, but a value of 1600 units per ml of solution with
T2 DNA as template. Higher enzymatic activity with T2 DNA,
as compared to calf-thymus DNA, is indicative of an enzyme
having a high content of a-subunit (Burgess, 1969) . . Indeed,
the rifampicin experiments described below {section 6a of
Results) indicate that the RNA polymerase had approximately
65% of the activity expected if all enzymatic protein were
active holoenzyme {Mangel and Chamberlin, 1974a).
3.

The Inhibitors

Actinomycin D was obtained from Calbiochem.
was obtained from Sigma.
i

C•lbiochem.

Rifampicin

Ethidium bromide was purchased from

Ethidium bromide analogs were the generous gift

~

of Dr. T. I. Watkins of Boots Company Ltd., Nottingham,
England.

The chemical formulae, molecular weights, molar

extinction coefficients and DNA binding parameters of these
compounds are given in Table 1 (seep. 39).
tinction

c~efficients

The molar ex-

shown in this Table are based on the

formula weight of the compounds and were determihed from the
absorption spectra of carefully prepared solutions at a
concentration of 1-2 mg/25 ml in 0.04 M Tris-HCl pH 7.9 at

f
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room temperature.

More detailed studies of the optical

properties of the DNA complexes of these compounds are
described by Kindelis (1976).
4.

Determi'nation of Binding Parameters

The spectrophotometric method of Peacocke and Skerett
(1956) was used to determine the binding constant and the
maximum number of binding sites per DNA nucleotide for each
drug on calf-thymus DNA.
In a typical experiment, calf-thymus DNA (2-3 mg/ml)
was dissolved under slow stirring at a-5°C in binding buffer
consisting of a.2 M KCl, a.a4 M Tris-HCl, a.al M MgC1 2 ,
0.1 mM EDTA, a.32 mM K2HPa 4 , pH 7.9. Then, the solution
was dialyzed overnight against binding buffer at a-5°C, and
filtered by suction through a GF/C filter (Whatman).

The

concentration of DNA in the filtrate was determined spectraphotometrically in the Cary 15 at 26a nm, using a molar
ex.tinction coefficient of 66aO

(Mahler~

!l_., 1964).

Solutions of increasing DNA/drug ratio were prepared
by adding increasing amounts of the DNA solution into
constant amounts of the drug solution in binding buffer
and bringing the mixture to the same final volume (la ml)
with buffei.

Identical solutions containing DNA, but no

inhibitor, were also prepared and used as reference in
the double-beam Cary 15 spectrophotometer.

The total

drug concentration (I ) was determined from the absorption
0

,.
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spectrum of a solution prepared as above, but in the absence
of DNA.

The amount of drug (around 20

~M)

was chosen so

that the absorbance at Amax of the resulting solution would
be approximately 1.0.

After mixing, each solution was

transferred into a 10.00 em path, water jacketed optical
cell (Hellma) that was kept at 37°C with the help of a
Lauda K-2R constant temperature circulator, and after
thermal equilibration the difference absorption spectrum
was recorded vs. the corresponding reference solution.
The absorption spectra of the DNA complexes of all
the drugs examined displayed the qualitative features
described by Kindelis (1976) for the complexes of the same
compounds formed under different ionic environment.

In

every case sharp isobestic points were observed in the
area 380-400 nm and 460-500 nm.
The absorbance of each sample (Ax) and that of the
11

total

11

drug (A 0 ) were read off the chart paper at a given

wavelength, chosen for best accuracy so that A0 -Ax is
maximum.
The absorbance of the completely bound drug {Ab)
was calculated with the graphic method of Li and Crothers
(1969) who have demonstrated that a plot of l/A 0 -Ax !!·
l/[DNA]-[1 0 ] yields a straight line with an intercept on
the ordinate equal to l/A 0 -Ab.
intercept, Ab may be calculated.

From the value of this
Determination of Ab with

this graphic method is much more accurate than the alternative
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method of reading off the chart paper the absorbance of a
solution prepared with very high DNA concentration (at very
high DNA concentration all of the drug is assumed to be
bound; i.e., Ax= Ab).

Concentrated DNA solutions required

to saturate the drug at 37°C in 0.2 M KCl absorb light
strongly, probably due to scattering and introduce error
in the determination of absorbance.
From these values, the fraction of DNA-bound inhibitor
(b) was calculated using equation (1).

( 1)

The molar ratio of inhibitor bound to DNA per nucleotide (rb) as well as the concentration of "free," unbound
r

inhibitor (If) and bound inhibitor (Ib) were calculated using

'

equations (2) and (3), respectively.

(2)

(3)

Then, the values of the apparent dissociation constant
(kapp) and the maximum number of binding sites per DNA
nucleotide (n) were obtained from the slopes and intercepts
of plots constructed according to Scatchard (1949) and
described by equation (4).
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(4)

5.

Enzymatic Activity Assays

In this work, enzymatic activity was always determined
by measuring the incorporation of radioactivity from a
radioactively labelled nucleoside triphosphate substrate
into material insoluble in 5% trichloroacetic acid.·
A typical reaction mixture consisted of a buffer
solution,

r2

DNA, RNA polymerase, the inhibitors (if any)

and an equ.imolar mixture of the four nucleoside triphosphates
~ith

one, or more, of them radioactively labelled.

These

components were transferred with fixed needle Hamilton
syringes into 10 x 75 mm disposable glass test tubes fitted
loosely with plastic caps.

(A Hamilton syringe fitted with

an Oxford pipette disposable plastic tip was used for
transferring the r 2 .DNA in order to avoid any nicking or
breaking due to shear.) The test tubes had been kept at
140°C for at least 48 hrs prior to use, in order to
inactivate any contaminating ribonuclease activity.

The

same treatment was given to all glassware used to prepare
assay buffers.

Alternatively, containers were washed with

a dilute solution of NaOH which destroys ribonuclease.
Care was exercised to handle all equipment with plastic
disposable gloves.

The two main types of experiments

conducted under these conditions are described below.

32
a.

Experiments Not Involving Rifampicin

In experiments designed to study the effect of
inhibitor on the rate of RNA synthesis in the presence of
a constant amount of DNA, the concentration of T2 DNA was
30 ~~· This concentration was chosen so as to correspond
to the minimum amount of DNA required in order to saturate
the activity of 4

~g

of RNA polymerase under the conditions

described below.

This amount of DNA corresponds to a molar

ratio of enzyme to T2 DNA initiation sites of the order of
25 since the number of such sites per T4 DNA molecule is
approximately 22 (Bautz and Bautz, 1970).
In these experiments, 37

~1

of 2.5X concentrated assay

buffer A was mixed with the appropriate amounts of T2 DNA
to yield final concentrations of 0.2 M KCl, 0.04 ~ Tris-HCl,
0.01 M MgC1 2 , 0.1 mM EDTA, 0.32 mM K2HP0 4 , 0.1 mM dithiothreitol, 0.4 mg/ml BSA, at pH 7.9 and 25°C. Inhibitor
(if any) was added and the solution was brought up to 84
wi'th deionized distilled water at 0-5°C.

~1

The mixture was

transferred to a 37°C bath and, after 6 min, the enzyme
(4

~g)

was added in 8

~1

of a solution consisting of 3

of assay buffer A (concentrated 2.5 times}, 3
deionized water and 2

~1

~1

~1

of

of the commercial enzyme solution.

Seven minutes later the reaction was initiated by the rapid
addition of a solution consisting of 0.8 mM each of ATP, GTP
and CTP and 0.4 mM 8-[ 3H]-U!P (specific activity 0.010
~Ci/nmol

or 0.1

~Ci/nmol

depending upon the experiment)
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in 8 vl of water adjusted to pH 7.9 with 1.0 M Tris-base.
The reaction was allowed to proceed for exactly 7.0 mfn
and then it was terminated through the rapid addition of
0.5 ml of an ice cold solution containing 0.1 M sodium
pyrophosphate and 2 mM UTP (or 0.02 M ATP or GTP for the
initiation experiments) followed by 0.5 ml of ice cold 11%
TCA- 1.0 M KCl - 0.01 M sodium pyrophosphate solution.
After mixing and standing in ice for at least 10 min
the insoluble material was collected by filtration through
a Whatman (2.4 em

diam~ter)

GF/C filter.

The filter was

rinsed with 15 ml of ice cold 5% TCA- 1.0 M KCl - 0.01 M
sodium pyrophosphate solution followed by 30 ml of 95%
ethanol, was dried under suction and at 105°C for 3 min
and, finally, counted under 0.4% 2,5-diphenyloxazole in
toluene solution in the Beckman LS counter.
Experiments designed to measure the inhibition of
0

y-

32 P-incorporation, which is a measure of the inhibition

of RNA chain initiation, were conducted exactly as
described above, with y- 32 P-labelled ATP or GTP (specific
activity 1.0 vCi/nmol) and final nucleoside triphosphate
concentration 0.2 mM in ATP, GTP, CTP, and 8-[ 3H]-UTP
{specific activity 0.01

~Ci/nmol).

A specific washing procedure for experiments involving
incorporation of 32 P was employed in order to decrease the
background of unincorporated radioactivity.

The filters

were washed with 100 ml of the TCA-KCl-pyrophosphate solution

34

mentioned above followed by 60 ml of 80% ethanol
subsequently stirred before drying and counting.

~nd

were

Identical

3H-cpm were recovered after this treatment indicating 'that
product is not lost.
Simultaneous counting of samples containing both 32 p
and 3H was effected with the Beckman Isoset system with a
gain setting of 3.0.

Under these conditions no Tritium
spill-over could be detected in the 32 P-above- 3H wi~dow,
while less than 2% spill-over from 32 P was detectable in
the 3H-below- 14 c window.
b.

Experiments Involving Rifampicin

As described in the Introduction, these experiments
were designed in order to measure the effects of various
inhibitors on the rate constants governing the initiation
steps of RNA synthesis.

All experiments were conducted

in buffer B consisting of 0.04 M Tris-HCl, 0.02 M MgC1 2 ,
0.1 mM EDTA, 0.32 mM K2HP0 4 , 0.1 mM dithiothreitol, 0.8
mg/ml BSA pH 7.9 at 25°C (Mangel and Chamberlin, 1974a).
Experiments measuring the rate of RNA synthesis as
a function of preincubation time were conducted as follows.
The buffer solution (37

~1)

at 2.5 times the final desired

concentration was mixed with the desired amount of inhibitor,
template {50

~M

T2 DNA) and deionized water to a final
volume of 72 ~1. After standing in ice for at least 10
min, the enzyme (4

~g)

was added in 8

~1

of a solution
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consisting of 3 pl buffer B (2.5 times concentrated), 3

~1

deionized water and 2 ul of the commercial enzyme preparation.

After 10 more minutes at 0°C the test tube containing

the above mixture was transferred into a 30°C bath for the
desired time.

The reaction was then initiated by the rapid

addition of an XTP-rifampicin mixture in 20 ul 0.04 M TrisHCl pH 7.9.

This mixture had been equilibrated at room

temperature and was prepared so as to result in final assay
concentrations of 30 pg/ml rifampicin and 0.4 mM XTP
(specific activity 0.10 uCi/nmol 8-[ 3H]-ATP). For the
control reaction rifampicin was omitted and an equal volume
of deionized water was used instead.

After exactly 1.5 min

of incubation at 30°C the reaction was terminated and each
mixture was processed as described under section Sa.
In experiments designed to measure the rate of RNA
synthesis as a function of rifampicin concentration the
buffer solution, the inhibitor, the DNA (90 uM) and
deionized water were mixed in the same manner as described
above.

Then the enzyme (2 ug in 8 ul) was added and the

mixture was preincubated for 7 min at 30°C.

The reaction

was initiated by the addition of an XTP-rifampicin mixture
prepared so as to result in 0.4 mM XTP (specific activity
0.10 uCi/nmol 8-[ 3H]-ATP) while providing the_ desired final
rifampicin concentration.

After 1.5 min at 30°C the

reaction was terminated and each mixture was processed as
described above.

In these experiments the enzyme to T2 DNA
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initiation sites ratio was either 15 or 40, assuming that
65% of the protein is active holoenzyme.

This ratio is

higher than the ratio of 1 used by Mangel and Chamberlin
(1974) with T7 DNA. The use of excess enzyme ensures that
the total number of initiation sites participates in
product formation.
In all experiments measuring incorporation of radioactivity into 5% TCA insoluble product, background values
were determined by treating identically a complete reaction
mixture not containing enzyme.

Background values were less
than 200 cpm in experiments involving 3H and less than

700 cpm in experiments using 32p.
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RESULTS
1.

The Binding of Phenanthridines to DNA

The binding of ethidium bromide and a number of
structural analogs of this phenanthridine to DNA has been
extensively studied (Kindelis, 1976; Waring, 1974).
However, in order to obtain a quantitative measure
of the distribution of the drug between the templatebound and the free forms under the ionic environment ·and
temperature conditions of the assays used for determining
rates of RNA synthesis, the binding parameters for each
drug must be determined under those conditions.
However, three of the compounds shown to inhibit
RNA synthesis exhibited complex spectroscopic characteristies
(Kindelis, personal communication).

The reasons for such

a behaviour could be attributed to the fact that complexes
of DMNC with DNA were only partially soluble, MMPB was not
completely soluble at the desired concentrations and DDEB
appeared to aggregate at high concentrations.
Binding experiments leading to the calculations of
rb (the molar ratio of drug bound per DNA nucleotide) and
If (the concentration of free drug) were conducted as
described under the Methods.

The values of the apparent

dissociation constant (kapp) and the maximum number of
binding sites per DNA nucleotide (n) were obtained from
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the slopes and intercepts of plots constructed according
to Scatchard (1949) and described by the equation

=

(4)

The Scatchard plots for EM, MAPEC, OEMS and DMEB are
shown in Figure la and b.

The values of kapp and n,

calculated for each drug are listed in Table 1.

Comparison

of the values in Table 1 and inspection of the plots in
Figure 1 allow the following conclusions to be drawn:
a)

The intrinsic affinities for DNA of all four drugs

as well as the corresponding number of binding sites are
similar in magnitude.
b)

Only one type of binding, i.e., binding to primary

sites in which the bound drug molecules are intercalated
between neighbouring base pairs is evident.

Drug bound

weakly to secondary sites on the outside of the DNA helix
is not present to an appreciable extent as indicated by
the linearity of the Scatchard plots and the magnitude of
n.

This binding behaviour is expected at relatively high

(0.2 M KCl) ionic strengths (Wariny, 1965b).

Table 1.

Chemical Structure and Properties of some Phenanthridinium Derivatives

kdiss
(llM)

n

5600479

18.9

0.19

332

3900463

32.2

0.19

DEMB

332

4700463

38.1

0.18

3,8-diamino-5,6-diethylphenanthridinium Bromide

DDEB

346

4100463

3,8-diamino-5-methyl-6-nonylphenanthridinium Chloride

DMNC

386

4900467

8-amino-6-p-aminophenyl-5-ethylphenanthridinium Chloride

MAPEC

349

4800431

32.4

0.17

8-amino-5-methyl-6-phenylphenanthridinium Bromide

MMPB

365

3650430

Systematic Name

Abbreviation

MW

3,8-diamino-5-ethyl-6-phenylphenanthridinium Bromide

EM

394

3,8-diamino-5-ethyl-6-methylphenanthridinium Bromide

DMEB

3,8-diamino-6-ethyl-5-methylphenanthridinium Bromide

8

Em ax

3
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Figure 1.
a)

Scatchard plots for some phenanthridines.

EB, -t-; MAPEC,

-!-.

b) DMEB, -•-; DEMB, -6-.

Experiments were conducted at 37°C in binding buffer
(0.2 M KCl, 0.04 M Tris-HCl, 0.01 M MgC1 2 , 0.1 mM
EDTA, 0.32 mM K2HP0 4 , pH 7.9 at 25°C) with calfthymus DNA as described under Methods. The amount of
the DNA was varied between zero and 6 mM while the
concentration of each phenanthridine was chosen so
as to yield an absorbance reading of 1.0 at the maximum wavelength.
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2.
~

The Effect of Template Concentration on Inhibition

Waring (1965a) has demonstrated that ethidium bromide

~

f

inhibits RNA synthesis competitively with the template, by
determining the level of enzymatic activity as a function
of template concentration in the absence and in the presence
of a constant amount of inhibitor.

In the present study,

similar experiments were performed with MAPEC, DEMB, and
DMEB, the structural analogs of ethidium bromide, and the
data were plotted as activity-l ~· [DNA]- 1 . In each of
the double reciprocal plots shown in Figure 2a, b and c,
the lines for the inhibited and uninhibited reactions are
crossing over on the activity axis indicating that the
inhibitory effect of the drug would be completely alleviated
at infinite DNA concentrations.

It may also be noted that

in the presence of inhibitor the double reciprocal plots
shown ip Figure 2a, b and c are curvilinear, a characteristic which becomes more pronounced at the higher drug
concentrations.

This apparently abnormal behaviour, whicb

has previously been noted by Waring (1965a) will be
discussed in a later section.
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Figure 2.

The effect of template concentration on the rate

of RNA synthesis either

i~

the absence of inhibitor, -•-,

or in the presence of the following amounts of inhibitor:
a) 14.0 uM MAPEC; b) 11.0

u~

DMEB; and c) 15.0 uM OEMS.

Experiments were conducted in 0.1 ml of assay buffer A
containing 0.8 mM each of ATP, GTP and CTP, 0.4 mM 8-[ 3 H]UTP (0. 1 uCi/nmol), 4 ug RNA polymerase and increasing.
amounts of r 2 DNA.

Reaction time was 7 min at 37°C.
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3.

The Effect of Drug Concentration on Enzymatic
Activity

In order to study in more detail the inhibitory effect

J

of the phenanthridines on RNA synthesis, experiments were

J

performed in which increasing amounts of drug were mixed

r with constant amounts of DNA, enzyme and substrate [XTP]
p
~

i

~
J!

t
1~

and assayed for RNA polymerase activity.
The phenanthridinium derivatives studied may be
characterized as strong inhibitors of RNA

polymerase~

since

inhibitor concentrations as low as 50 uM were found to

l
~

data as activity (per cent) Yi· inhibitor concentration

~
r

(Figure 3a and b) reveal that the activity curves of all

f

cause complete inhibition of RNA synthesis.

Plots of the

compounds studied displayed the same overall shape.
Enzymatic activity gradually decreases with increasing
concentration of inhibitor up to a certain point where a
sharp decline in activity is observed with a small increase
in inhibitor concentration, followed by a much slower
further decrease in activity which eventually reaches the
zero (per cent) level at very high inhibitor concentrations
(above 50

u~).

These qualitative similarities seem to

suggest a mechanism of inhibitory action common to all
drugs.
However, important quantitative differences are also
evident.

Ethidium bromide, which causes 40% inhibition at
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Figure 3.

The effect of phenanthridine concentration on the

rate of RNA synthesis relative to the uninhibited reaction.
The maximum activity (100%} corresponds to the incorporation of 2.5 x 10 4 cpm into product insoluble into 5% TCA.
Reactions were conducted in 0.1 ml of assay buffer A containing 0.8 m~ each of ATP, GTP, and CTP, 0.4 m~ 8-[ 3 ~]UTP (0.01

~Ci/nmol},

4

~g

RNA polymerase and 30

~M

T2 DNA

for 7 min at 37°C.
a}

Each bar represents the standard deviation of

the mean of twelve determinations for EB, -•-; MAPEC, -A-;
DMEB, -o-, DEMB, -•-.

Standard deviation of the mean (a)

was calculated using the formula

where x is the experimental value and N is the number of
values.
b)

The experimental points are less accurate than

those of Figure 7a due to the fact that complexes of DMNC,
-o-, with DNA were partly soluble in the assay mixture;
MMPB, -1-, was not completely soluble at the desired
concentration; DDEB, -v-, appears to aggregate at high
concentrations.
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a concentration of only 4.5

u~

as compared with DEMB, for

which 14.5 uM are required to reach the same level of
inhibition, appears as the strongest inhibitor.

Table 2

lists the drug concentration for which 40% inhibition is
reached.

The values are determined from the plots in

Figure 3a and b.

It may be observed that maximum inhibitory

capacity appears to be associated with the presence of
large hydrophobic groups at position
thridinium ring.

~of

the phenan-

The effect of the relatively large,

hydrophobic phenyl or nonyl groups, in the case of EB and
DMNC respectively, is particularly apparent if the
inhibitory effectiveness of these two drugs is compared
with that of ·DDEB, DMEB or DEMB, i.e., compounds that carry
the smaller methyl or ethyl groups at the same position.
Only 4.5 uM and 7.0 uM of EB and DMNC respectively are
required for 40% inhibition, which is two to three times
less than the concentrations of DDEB (12.5 uM), DMEB
(13.5 uM) or DEMB ( 14. 5 uM) required for the same inhibitory
effect.
The inhibitory effectiveness of MMPB relative to EB
can only be tentatively assessed due to the apparent
solubility problem associated with the former compound (see
legend to Figure 3b}.

Specifically, it appears that the

absence of an amino group at position 1 of the molecule
renders the compound a much weaker inhibitor.

Again much

less EB (4.5 uM} is required than MMPB (11.0 uM) in order
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Table 2.

Comparison of the Pharmacologic and Inhibitory
Effectiveness of some Phenanthridines

Compound

Trypanocidal
Activity*
(Dimidium = 1)

Concentration
Resulting in 40%
Inhibition (ll!1)

EB

10.00

4.5

DMNC

Active**

7.0

MAPEC

0.50

MMPB

9.3
11.0

DDEB

0.22

12.5

DMEB

0.12

13.5

DEMB

0.10

14.5

*Data compiled from the Median Curative Dose determinations
of Woolfe, G., (1956a, b).
**Active indicates trypanocidal activity below 0.10 relative
to dimidium.
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to inhibit RNA synthesis to the same extent (Table 2).
The relative inhibitory strength of EB and MAPEC, another
derivative lacking the amino group at position 1 but
carrying a second amino group at the para position of the
phenyl substituent, seems to support the same conclusion,
i.e., the absence of the amino group at position 1 renders
a compound a weaker inhibitor than ethidium bromide.

\
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4.

The Effect of

DNA~bound

Inhibitor on RHA

Synthesis
Ethidium bromide has been shown to inhibit RNA
synthesis by inactivating template molecules, not enzyme
molecules, as a result of the association of the drug with
template (Waring, 1965).

Consequently, the active

ethidium bromide as an inhibitor of RNA synthesis
is the DNA-bound form of the drug.

An appropriate means

of expressing quantitatively the concentration of the
active form of ethidium is in terms of the ratio of drug
· m~lecules bound per DNA nucleotide (rb).

This ratio,

however, does not depend linearly on the total drug
concentration (see equation 5, section 7 of Results), a
factor which may become particularly important in comparative studies of the inhibitory effectiveness of the structural analogs of ethidium bromide which have similar, but
not identical affinities for the DNA template.
In order to establish that the differential inhibitory
capacity of the phenanthridines is not simply the result
of their different affinities for the DNA template, the
dependence of RNA polymerase activity was determined as a
function of rb of each drug.
The values of rb were calculated for each drug using
equation 4, section 1 of Results, and were subsequently
employed in plots of RNA polymerase activity (%) as a
function of rb.

In Figure 4, the enzymatic activity appears

56
to depend linearly on rb in the range between 90% and 15%
with either ethidium bromide or its derivatives as the
inhibitor.

A similar observation regarding the linear

dependence of RNA polymerase activity on the rb of
ethidium bromide has also been made by Waring (1965a).
The compounds included in Figure 4 exhibit clear
differences in their inhibitory capacity against RNA polymerase.

Comparison of the values of enzymatic activity

remaining at a value of rb

= 0.04 reveals that EB is the

strongest inhibitor among these compounds, effecting a
54% decrease in enzymatic activity, while at the same value
of rb MAPEC, DEMB and DMEB decrease the activity of RNA
polymerase by 49%, 26% and 17% respectively (Table 3).
These results indicate that identical numbers of bound
inhibitor molecules per molecule of DNA have different
inhibotory effects on the ability of RNA polymerase to
utilize this DNA as a template for RNA synthesis.

Conse-

quently, the inhibitory effectiveness of these phenanthridines is determined not only by the affinity of each compound
for the template, but also by the specific structure of
each intercalated inhibitor molecule.
Table 3 also lists the values of rb of each drug
which result in total inhibition of RNA synthesis (r 10) as
obtained by ~xtrapolating the linear portion of the curves
in Figure 4 to zero activity.

From these values it would

appear that on the average, intercalation of one inhibitor
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Figure 4.

Dependence of the rate of RNA synthesis on

the concentration of the template-bound form of the
inhibitor.

EB, -e-; MAPEC, -A-; DMEB, -o-; DEMB, -•-.

Plots constructed on the basis of the inhibition data
shown in Figure 3a.
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Comparison of the Inhibitory Effectiveness of
the Template-Bound Forms of the Various
Inhibitors

Inhibitor

rb, 40%

r I, 100%

Decrease in
Activity (%)
at rb = 0.04

EB

0.032

0.068

54

MAPEC

0.036

0.058

49

DEMB

0.048

0.077

26

DMEB

0. 051

0.080

17

40% is the ratio of bound inhibitor per DNA nucleotide
required for 40% inhibition.
100% is the ratio of bound inhibitor per DNA nucleotide
that effects total inhibition. r1, 100% is obtained
by extrapolating the linear portion of the curves shown
in Figure 4 to zero activity (%).

60

molecule per seven base pairs can completely abolish the
template properties of the DNA when measured by this
method.

The significance of this observation with respect

to the mechanism of template inactivation will become
apparent in a later section •

•
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5.

Ethidium Bromide Analogs Limit the Number of
RNA Molecules that can be Initiated without
Interfering Significantly with the Elongation
of Initiated Chains

One method for determining whether a given compound
inhibits RNA synthesis by interfering with RNA chain
initiation and/or chain elongation is to study the incorporation of radioactivity from two different substrates
simultaneously, i.e., the incorporation of a y-[ 32 P] ·labelled
purine triphosphate nucleoside and a [ 3H] or [ 14 c] labelled
nucleotide triphosphate as described by Maitra

~

!l·

(1967).

In order to determine whether the structural analogs
of ethidium bromide inhibit one or both steps involved in
RNA chain synthesis, the simultaneous incorporation of
radioactivity from a y-[ 32 P]-ATP - [ 3H]-UTP and a y-[ 32 P]GTP - [ 3 H]-UTP system was measured as a function of inhibitor
concentration.

The results are shown in Figure 5a, b, c and

The decline in product formation in the presence of
increasing amounts of inhibitor (as evidenced by [ 3H]

d.

incorporation) loosely parallels the decline in the number
of chains being initiated with either ATP (as evidenced by
[ 32 P] incorporation from y-[ 32 P]-ATP) or GTP (as evidenced
by [ 32 P] incorporation from y-[ 32 P]-GTP) as the first
nucleotide.

This behaviour indicates that ethidium bromide

analogs inhibit RNA synthesis mainly by limiting the number

f
J
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f

of chains that can be initiated rather than by reducing the

f

growth rate of initiated chains.

•

,;

Using this method with circular DNA from Pseudomonas
phage 2 as template, Richardson (1973a) found that ethidium
bromide inhibits RNA chain initiation without interfering
with chain elongation.

However, with a linear template,

ethidium bromide appeared to inhibit to a significant extent
chain elongation as well, especially at high inhibitor
concentrations.
The extent to which each drug inhibits (in addition to
its primary effect on chain initiation) chain elongation is
quantitatively depicted in the insets to Figure Sa, b, c
and d. Theoretically the ratio [ 3 H]/[ 32 P] is a measure of
the degree of polymerization of the average product chain.
In the extreme case characterized by inhibition of initiation
and the absence·of any effect of the inhibitor on the rate
of chain elongation, the degree of polymerization of the
should remain constant with increasing inhibitor
concentration, i.e., the [ 3H]/[ 32 P] ratio should exhibit a
p~oduct

slope of zero.

In the case where inhibition is exerted

only at the level of chain elongation, a line with a
negative slope should be obtained.

The slope of this line

should be equal to that of the activity
concentration curve.
both

st~ps

~·

inhibitor

Accordingly, compounds inhibiting

of RNA synthesis_ would be expected to yield lines

of negative slopes, the steepness of which would be a
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Figure 5.

Inhibition of the rate of total RNA synthesis
and the rate of RNA chain initiation. [ 3H]-UMP incorporation, -o-; y-[ 32 P]-ATP incorporation, -a-; y-[ 32 P]GTP incorporation, -!-; for a) EB; b) MAPEC; c) DMEB
and d) DEMB. In each case, the ratio of %[ 3 H] vs •
......

%[ 32 P] incorporation, -o-, was calculated using the
formula

=
This formula is used because, in the absence of inhibitor,
four RNA molecules are initiated with ATP for every molecule initiated with GTP as determined by the molar ratio
of A-starters to G-starters.

This ratio was calculated

from these data under conditions of identical UMP incorporation. 2.5 x 10 4 cpm of [ 3H]-UMP, 5 x 10 3 cpm of
y-[ 32 P]-ATP and 2 x 10 3 cpm of y-( 32 P]-GTP were incorporate
in the absence of inhibitor.

Each bracket represents

standard deviation of the mean of six determinations.

The

DNA concentration was 30 uM. The specific activity of
y-[ 32 P]-labelled nucleotides was 1.0 uCi/nmo1 and that of
8-[ 3H]-UTP was 0.01 uCi/nmol.
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measure of the relative degree of inhibition of the initiation
and elongation steps.
The two strongest inhibitors, EB and MAPEC, appear
to have, in addition to their major effect against RNA
chain initiation, a minor effect on the rate of chain
elongation as well.

The negative slope observed in the

inset to Figure Sa indicates that with a linear DNA such
as T2 DNA as template high concentrations of ethidium bromide
decrease to some extent the rate of elongation although the
main effect is still exerted on the number of chains that
can be initiated.

This result is in agreement with previous

reports (Richardson, 1973}.

MAPEC appears to inhibit chain

elongation to a lesser degree than ethidium bromide as
indicated by the reduced slope of the curve in the inset
to Figure Sb.

On the other hand, both DMEB and DEMB appear

to behave essentially as initiation inhibitors and have
a very small, if any, effect on RNA chain elongation
(Figure Sc and d).

DMEB and DEMB may therefore be used

most profitably in studies of the mechanism of inhibition
of RNA synthesis by chain initiation inhibitors.
Some information, albeit tentative, about the relative
number of RNA molecules starting with ATP

~'

GTP may be

obtained from the activity curves in Figure Sa, b, c and d.
Under the conditions of these experiments a ratio of A to G
starters of A was observed.

This ratio which depends

largely on experimental conditions is within the range of
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1-6 observed with holoenzyme and
(Maitra

~

!l·,

1967}.

r4

DNA as template

Under experimental conditions

different from those used here, a ratio of 1.3 was obtained
with T2 DNA as template (Maitra ~ !l·• 1967}. It may be
observed that in every case the incorporation of radioactivity from y-( 32 P]-GTP declines faster with increasing
inhibitor concentration than the incorporation from y-( 32 P]ATP.

It thus appears as if the initiation of RNA molecules

which carry GTP as their terminal 5' nucleotide (G-starters}
is inhibited more effectively than RNA molecules with an
ATP as their 5' terminal nucleotide (A-starters}.

This

finding, which pertains to a linear DNA, is in contrast to
a previous report (Richardson, 1973) that A-starters are
inhibited by EB more effectively than G-starters when a
circular DNA templlte from Pseudomonas phage£ is used.
It is possible that the physical state of the template is
responsible for the preferential inhibition of A-starters
by ethidium bromide when the superhelical PM2 DNA is used
as template.

However, the relatively high experimental
error associated with measurements of [ 32 P] incorporation
in experiments of this type requires a cautious interpretation of small differences in the exact values of the

activity curves as those observed in Figure 5a, b, c and d.
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6.

The Effect of Ethidium Bromide and DEMB on the
Steps of RNA Chain Initiation

Inhibitors of DNA-dependent RNA polymerase may be
expected to exert their effect at one or more of the various
steps involved in RNA synthesis.

Inhibition may be the

result of an alteration in either the rate or the number
of enzyme molecules traversing any given step or .a combination of the two effects.

In the previous section it was

shown that EB and DEMB inhibit RNA synthesis by limiting
the number of enzyme molecules that can form the first
phosphodiester bond of the product without significantly
affecting the rate of polymerization of the initiated
chains.

This limitation in the number of chains growing

in the presence of EB or DEMB results from the inhibition
of a step prior to the formation of the first phosphodiester bond and may, in turn, reflect an effect of the
inhibitor on the rate and/or the number of enzyme molecules
traversing that prior step or steps.
As described in the Introduction, two major steps
are presently recognized in the process of RNA chain
initiation by DNA-dependent RNA polymerase.

Methods which

allow the independent determination of the number and the
rate of enzyme molecules which are traversing each of these
steps have also been developed (Mangel and Chamberlin, 1974a
and c).

These methods when used in the absence and in the

r

r
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'

presence of an inhibitor, such as ethidium bromide or DEMB,
which have been shown not to inhibit chain elongation
appreciably, can provide information concerning the effect
of the inhibitor on either one or both of these parameters.
a.

Ethidium Bromide and DEMB do not Affect
the Rate of the Second Initiation Step

The effect of the two intercalating drugs ethidium
bromide and DEMB on the rate and the number of RNA polymerase
molecules traversing the second initiation step (see
Introduction) was studied by determining the level of
enzymatic activity as a function of rifampicin concentration
in the presence and in the absence of these inhibitors.*
The results of these experiments were analyzed according to
the equation described by Chamberlin (1974):

C*

=

k2

k*

· [rifampicin]

where CT and C* are the total binary RNA polymerase-DNA
complex concentration and the concentration of binary
complexes able to initiate an RNA chain respectively; and k2

*Heretoforth the terms inhibitor, inhibited reaction, etc.,
will be reserved only for intercalating compounds such as
EM, DEMB, actinomycin D, etc. Rifampicin, although a strong
inhibitor of RNA polymerase in itself, is merely being used
as a tool in these methods and will always be designated by
its full name.
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and k* are the rate constants for rifampicin attack on
binary complexes and RNA chain initiation respectively.
Since, under our experimental conditions, the measured
rates in the presence and the absence of inhibitor (v and
Vmax respectively) are proportional to the concentration
of the complexes, one can therefore write:
CT - C*
C*

=

vmax - v

v

=

[rifampicin]

The results plotted in each case as the ratio of the rate
of RNA synthesis without rifampicin (Vmax), divided by the
rate of RNA synthesis with rifampicin (v)
concentration are shown in Figure 6.

~·

rifampicin

The slope of each

line is a measure of the ratio of the rate constant of
rifampicin attack on the enzyme over the rate constant of
chain initiation through the second initiation step
(Mangel and Chamberlin, 1974a).

If we assume that the

rate of rifampicin attack on the enzyme is the same in
the presence as well as in the absence of inhibitor, then
the slope of each line in Figure 6 is a measure of the
rate constant of initiation through the second initiation
step.

The near identity of the slopes for the inhibited

and uninhibited reactions indicates that the presence of
either EB or DEMB has no effect on the rate constant of
RNA polymerase molecules which proceed from their RS
complexes to form the first phosphodiester bond.

These
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Figure 6.

The dependence of the relative rate of RNA

synthesis on rifampicin concentration.

The rate of

incorporation of radioactivity into product in the
absence of both inhibitors and rifampicin (Vmax> was
8.4 x 10 3 cpm. v is the rate of the reaction in the
presence of rifampicin only, -•-; in the presence of
rifampicin and an rb
presence of an rb
activity

= 0.035 for EB,

-a-; or in the

= 0.50 for DEMB, -o-.

Enzymatic

assayed in 0.1 ml of assay buffer B
containing 0.4 mM XTP (0. 1 vCi/nmol 8-[ 3H]-ATP), 2 vg
wa~

RNA polymerase and 90 vM T2 DNA. Reaction conditions
were 1.5 min at 30°C. The dotted line corresponds to
the theoretical curve that would be obtained using the
equation on page 72 in the presence of an inhibitor
causing a 25% decrease in the rate of the control
reaction (v) without affecting the number of active
enzyme molecules.

The slope of this curve relative

to the control reaction is a measure of the sensitivity of this method and demonstrates that all
experimental curves in this Figure are parallel to
one another within experimental error.
j

j
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results also indicate that it is unlikely that either EB
or DEMB Qffect the rate constant of rifampicin attack on
RNA polymerase.

Otherwise, these inhibitors would have

to exert two equal and opposite effects on the rate
constants governing initiation and rifampicin attack;
i.e., two distinct reactions among different reactants
and sites on the enzyme.

It is established that rifampicin

attacks the site responsible for nucleotide binding (Wu and
Goldwaith, 1969), while the DNA bound inhibitors would be
thought to interfere with the template binding site of the
enzyme.
The intercept of each line on the Vmax/v axis of
Figure 6 is, on the other hand, a measure of the maximum
number of RNA polymerase molecules which are able to
transform the RS complex to the rifampicin-resistant
ternary complex (Mangel and Chamberlin, 1974a).

In the

presence of EB at an rb of 0.035 and DEMB at an rb of
O.U50, the value for this intercept is 36y and 47%
respectively of the value of the uninhibited reaction
which indicates that both inhibitor·s strongly limit the
number of enzyme molecules that can traverse the second
initiation step.

It should be emphasized, however, that

the decrease in the Vmax/v intercept may be the result of
either one of two possible causes.

One possibility is

that EB and DEMB may limit the number of enzyme molecules
that can initiate directly by preventing the formation of
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the RS complex.

Alternatively, EB and DEMB may act by

inhibiting a step prior to the formation of the RS complex.
In either case, identical experimental results would be
expected since the method employed merely measures the effect
of the inhibitor on the maximum number of enzyme molecules
that cBn form RS complexes irrespective of the origin of the
effect.

Further experimentation is therefore necessary in

order to distinguish between these two possibilities.
b.

The Rate of RNA Polymerase Molecules
Traversing the First Initiation Step
is not Affected by the Presence of
Either Ethidium Bromide or DEMB

The effect of EB and DEMB on the rate and the number
of RNA po1ymerase molecules traversing the first initiation
step was studied by determining enzymatic activity as a
function of pre-incubation time of the I complex in the
presence and in the absence of rifampicin and one of the
intercalating inhibitors (Methods).

The results plotted

as activity (cpm)

~·

Figure 7a and b.

It is apparent that the curves in

pre-incubation time are shown in

Figure 7a and b display the same overall shape; i.e., a
rapid increase in the initial rate of incorporation of
radioactivity is observed during the first two minutes of
pre-incubation time, which is followed by a much more
gradual increase of this rate at longer times.

The control
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Figure 7.

The rate of RNA synthesis (cpm) as a

function of pre-incubation time (sec) in the absence,
-o-, and in the presence, -1-, of 30 ug/ml of
rifampicin.

a) in the presence of an rb

of EB with, -A-, or without,
b) in the presence of an rb
-A-, or without,

-~-,

-~-,

= 0.035

30 ug/ml rifampicin;

= 0.050 of DEMB with,

30 ug/ml rifampicin; c) a

composite plot of (a) and (b) showing the dependence
of the logarithm of enzymatic activity (%) at infinite
pre-incubation time, minus enzymatic activity (%) at
time (t)

~·

the pre-incubation time (t).

Activity

(%) is measured as the cpm incorporated in the presence
of rifampicin divided by the cpm incorporated in its
absence when no inhibitor was present, -o-, or when
EB, -A-, or DEMB, -1-, was present.

The activity

levels corresponding to 160 sec of pre-incubation time
are taken as the activity level at infinite time.
Enzymatic activity was assayed in 0.1 ml buffer B
containing 50

T2 DNA and 40 ug/ml RNA polymerase
as described under Methods. The nucleoside triphosphate
concentration was 0.4 m~ (0.1 uCi/nmol 8-[ 3H]-ATP).
u~
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reaction, obtained in the absence of both rifampicin and
inhibitor (see footnote on page 71 }, reaches maximum
activity within the first minute of pre-incubation time,
as expected (Mangel and Chamberlin, 1974c).
The gradual rise in activity observed between two
and thirty minutes of pre-incubation time appears to be
faster in the presence of both DEMB and rifampicin (or,
to a lesser extent, in the presence of EB and rifampicin)
than the rise in activity in the presence of rifampicin
alone.

As it will be discussed later, this apparent

paradox may be due to the ability of the enzyme to overcome
the inhibitory effect of DEMB (or EB) presumably by
displacing at a very slow rate the intercalated drug from
sites suitable for specific enzyme binding on the template.
Figure 7c was constructed for the purpose of
determining the half-life time of the I complex in the
presence and in the absence of inhibitor.

The incorporation

of ·radioactivity (%) at infinite pre-incubation time

(t~)

minus the incorporation of radioactivity {%) at time (t)
is shown in a logarithmic scale as a function of preincubation time (t).

(Incorporation of radioactivity

per cent is the cpm incorporated in the presence of
rifampicin divided by the cpm incorporated in its absence.)
(Mangel and Chamberlin, l974c).

The results obtained in

the absence of inhibitor as well as those obtained in the
presence of either DEMB or EB yield lines of similar slopes
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and intercepts indicating that the presence of the
intercalated inhibitor has little effect on the rate of
transformation of the I complex into the RS complex.
On the other hand, the data shown in Figure 7a and
b reveal that addition of EB or DEMB together with rifampicin in the enzymatic assay mixture drastically decreases
the level of incorporation of radioactivity by RNA polymerase
far below the level obtained when rifampicin is added alone.
These data indicate that both DEMB and EB have.a
strong effect on the enzymatic activity of RNA polymerase
above and beyond that exerted by rifampicin.

The fact that

the half-life time of the I complex is approximately the same
in the presence of rifampicin, rifampicin-plus-DEMB and
rifampicin-plus-ES indicates that neither DEMB nor EB
significantly affect the rate at which RNA polymerase
molecules can traverse the first initiation step.

Therefore,

the decreased level of activity in the presence of the
inhibitor would have to be attributed to a decrease in the
number of enzyme molecules that can form product.
c.

Evaluation of the Previous Results

Ethidium bromide and DEMB have been found not to affect
the rate constants of the elongation or the initiation steps
although they strongly limit the number of enzyme molecules
that can initiate a chain.

Yet, EB and DEMB do not inhibit
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each and every one of these steps, but they rather interfere
with only one step and the effect is being carried over to
the others.

Two facts allow this conclusion to be drawn.

First, concentrations of EB (0.035 rb) and DEMB (0.050 rb)
that were shown to

~ause

approximately 50% inhibition of

the overall enzymatic activity are found to produce roughly
the same degree of inhibition when each step is studied
independently of the other.

Second, the methods employed

for the study of the effect of inhibitor on each initiation
step merely measure the number of enzyme molecules that are
traversing each step in the presence and in the absence of
inhibitor, without providing any information as to which
particular step or steps are inhibited.

Inhibition of either

the recognition or the elongation step, for example, could
limit the number of enzyme molecules able to form product
equally well.

This fact, however, does not complicate the

determination of the rate constants of the initiation and
elongation steps which were specifically shown not to be
affected by the presence of either EB or DEMB.

It may

therefore be concluded that EB and DEMB do not affect the
rate constants of RNA polymerase traversing the initiation
or the elongation steps, while at the same time, these
compounds inhibit one of the steps involved in RNA synthesis.
The one step inhibited could be either the recognition step
or one of the initiation steps with the restriction that the
primary mechanism of inhibition must exclude an effect of
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the inhibitor on the rate constants of the two initiation
steps.

Formation of the non-specific complex has already

been shown not to be inhibited by EB (Richardson, 1973),
and the rate of chain elongation was shown in section 5
not to be significantly affected by either EB or DEMB.
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7.

-The Kinetics of Template Inactivation

In the previous sections evidence was presented that

oEMB exerts its inhibitory effect at a single step of RNA
synthesis ·by interfering with the formation of an enzymeDNA productive complex.

However, DEMB may inhibit the

formation of this complex through any one (or a combination)
or two distinct, general mechanisms.

On one hand, inter-

calation of the drug at a specific site of the template
might distort the conformation of that site so that the
enzyme would not be able to recognize the site and bind on
it productively.

In this case, the number of enzyme

molecules able to form product in the presence of DEMB
would be decreased although those enzyme molecules able to
recognize the binding site would be expected to synthesize
product at a rate unaffected by the presence of the inhibitor.
On the other hand, the presence of drug at a specific site
of the template might allow recognition by the enzyme to
take place, albeit at a slower rate.

In this case, the same

number of enzyme molecules could be active in the presence
of drug as in its absence, although in the presence of
inhibitor these active enzyme molecules would be expected to
form product at a reduced rate.
In order to distinguish between these two alternative
mechanisms, the effect of the inhibitor on the rate of
formation of productive complexes must be determined
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independently of the effect of the inhibitor on the number
of enzyme molecules which are able to form complexes of
this type.
In 1970, Shih and Bonner demonstrated that computer
fitting of experimental data of RNA polymerase activity as
a function of the concentration of the DNA template yielded
satisfactory fitting to an equation formally analogous to
the Michaelis and Menten equation, provided that the enzyme
concentration is kept constant.

It was thus shown that the

DNA template can kinetically be described as a substrate.
Accordingly, and for the purpose of deriving kinetic
equations, compounds believed to inhibit RNA synthesis by
interacting only with the template (substrate) may be
treated. as substrate inactivators, i.e., compounds that
exert their inhibitory effect by lowering the effective
concentration of the substrate.
For simple enzymatic systems, inhibition via substrate
ina~tivation

has been described (Westley, 1969).

However,

quantitative treatment of the inactivation of a large
template carrying many potential inhibitor binding sites
would require a more carefully defined and, therefore, more
complex description.

Nevertheless, the quantitative

description of such a system is greatly facilitated in view
of the fact that compounds such as EB and actinomycin D
have been shown to interfere.with the template function of
the DNA but not to act directly on the enzyme.

Accordingly,
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a general hypothesis can be introduced specifying that in a
oNA-drug inhibition system, a DNA-inhibitor (SI) complex may
form while an enzyme-inhibitor (EI) complex is not formed.
Then, the only additional assumptions to be made regarding
this system should concern the properties of any possible
ternary enzyme-substrate-inhibitor (ESI) complex.

Thus, it

may be assumed in turn, that {1) an ESI complex does not
form; (2) an ESI complex does form but it cannot lead to
product; (3) an ESI complex does form and does lead to
product, but it does so as fast as the ES complex; or (4)
that an ESI complex does form and does lead to product,
but it does so at a rate different than that of the ES
complex.

For each of these cases, equations can be derived

describing the dependence of enzymatic activity on the
concentration of DNA as shown in the Appendix.

In the

derivation of these equations it is assumed that all
complex formations preceding the chain elongation are
rapid with respect to the elongation step, in agreement
with all previous experimental observations.

These equa-

tions predict that double reciprocal plots of RNA polymerase
activity~·

substrate concentration (DNA), constructed on

the basis of experimental points obtained in the presence
of a constant rb of inhibitor, should produce straight lines
with intercepts on both axes characteristic of the mechanism
of inhibition.
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In order to test the suitability of the equations
describing quantitatively the effect of a rate inhibitor,
actinomycin D was used, which has previously been shown to
inhibit the rate of RNA chain elongation without affecting
the number of chains that are being initiated (Hyman and
Davidson, 1970).

At the same time, in a similar but

separate experiment, the kinetic behaviour of DEMB was
tested using the method described below.
Reaction mixtures were prepared in which the concentration of DNA and that of the inhibitor (actinomycin D or
DEMB) were adjusted so as to produce a constant ratio of
bound drug to DNA nucleotide (rb) as the absolute values
of concentration for both reagents were being increased.
The amount of inhibitor mixed with a given amount of DNA
in order to obtain a constant rb value was calculated
using equation 5, which is directly derived from the
Scatchard equation (equation 4, section 1 of the Results).

=

(5)

where [Io] is the concentration of the inhibitor to be
mixed with the concentration of DNA, [DNA].
The binding parameters (kdiss and n) shown in Table 1
were used for DEMB. For actinomycin D, the values reported
by MUller and Crothers (1968) were used, adjusted according
to Hyman and Davidson (1970), i.e., kdiss

= 0.7

~M.

n=
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0.110.

(The binding parameters for actinomycin D were

adjusted by taking into account the difference in the
temperature between the experimental conditions reported by
MUller and Crothers (1968) and those employed for the RNA
polymerase assays.)
The reaction mixtures used to assay RNA polymerase
in the presence of DEMB or actinomycin D were processed as
described previously (Methods) and the results were fitted
into double reciprocal plots of

activity~·

substrate

concentration [DNA] as shown in Figure 8.
a.

Inhibition by Actinomycin D

In the presence of constant rb of actinomycin D, the
intercept in Figure 8 on the reciprocal activity axis
(Vint) appears to be lower than the Vint of the uninhibited
reaction while the intercept on the reciprocal substrate
axis (Kint) has the same value with the uninhibited reaction.
This effect of the inhibitor on the values of Vint and Kint
is predicted only for "rate inhibitors" as shown in Table 5.
Therefore, among the various

mechan~sms

examined, actino-

mycjn D appears to fit only the mechanism predicted by
equation 13 of the Appendix.

This equation describes the

kinetic behaviour of compounds that inhibit RNA synthesis
by forming, with a productive enzyme-DNA complex, a ternary
complex which cannot break down to form product.

In other

words, actinomycin D does not interfere with the number of
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Figure 8.

Double reciprocal plots of the dependence

of the rate of RNA synthesis on the concentration of
the template in the absence of inhibitor, -•-, and in
the presence of DEMB at an rb

= 0.055, -a-, or

actinomycin D at an rb = 0.00085, -o-.

Each experi-

mental point represents the mean of three determinations; standard deviation of the mean was less than 9%.
RNA polymerase (4

~g)

was assayed in 0.1 ml of buffer A

containing 0.8 mM each of ATP, GTP and CTP and 0.4 mM
8-[ 3H]-UTP (0. 1 ~Ci/nmol). Reactions were carried out
for 7 min at 37°C as described under Methods.
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enzyme molecules forming productive ES complexes, although
it eventually combines with such a binary complex to form
an inactive ternary ESI complex.

Since actinomycin D

inhibits the rate of chain elongation, the large majority
of the ESI complexes must be formed between the inhibitor
and the propagating binary complexes.

Formation of the

ESI complex forces the enzyme to terminate synthesis since
the ESI complex cannot break down to form product.
This model is in agreement with the well accepted
view that actinomycin D inhibits RNA synthesis by decreasing
the growth rate of the RNA chains without interfering with
the number of RNA chains which are being initiated (Maitra
et

~.,

1967; Hyman and Davidson, 1970).
b.

Inhibition by DEMB

In the presence of a constant rb of DEMB the intercept
of the plot shown in Figure 8 on the reciprocal substrate
axis (Kint) appears to be larger than the Kint of the
uninhibited reaction, while the intercept on the reciprocal
activity axis {Vint> has the same value with the uninhibited
reaction.

This effect of DEMB on the values of Kint and

V.1n t is distinct from the pattern predicted for actinomycin D
by

equation 13, but appears to be in general agreement with

the pattern predicted by either equation 11 or equation 15
of the Appendix (see also Table 4).
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Table 4.

Intercepts of Double Reciprocal Plots

Type

Intercept on
Velocity Axis
(Vint)

Intercept on
DNA Substrate
Axis (Kint)

---------------------------------------------~-----------

No Inhibition

1

1

K•

vmax
Binding Site
Inactivation

11

Rate

11

Inhibition

Mixed Binding
Site Inactivation

Mixed Inhibition

1

1-rb

vmax

K•

1
Vmax(l-rb)

1
1

K•

1

1

1-rb

- - + K3·rb

Vmax
(1-rb) + K3·K•l.rb

1

K•

-

Vmax(l-rb) + V~ax·K3·rb

1

1-rb

- - + K3·rb

K•

1
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In order to distinguish graphically the pattern
predicted by equation 11 from the pattern predicted by
equation 15, the set of experimental data obtained in the
presence of constant DNA concentration described in section
4 was used.

For experiments carried out in the presence

of constant DNA concentrations equation 11, but not

equation 15, predicts that a plot of
1

vs.
v

should yield a straight line having an intercept of 1.0
on the activity axis.

Accordingly, if DEMB follows the

mechanism corresponding to equation 11, then a plot constructed with the experimental data obtained in section 4
should yield the pattern predicted by this equation.
Nevertheless, when this plot is constructed, a curve of
increasing slope instead of the expected straight line is
obtained (Figure 9).

However, when the same data are

plotted as
vs.

1

(where r

has the value shown in Table 3) a straight line
1
is obtained with an intercept of approximately 1.0 on the
activity axis (Figure 9).

This latter plot is not the
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Figure 9.

A double reciprocal plot of the dependence

of the rate of RNA synthesis on the ratio of DEMB bound
per DNA nucleotide (1 - rb)' -o-; or the same ratio
divided by the ratio of DEMB bound per DNA

nucle~tide

that results in complete inhibition (1 - rb/r 1 ), -1-.
The graphs are replots of the data shown in Figure 4.

J
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result of an arbitrary modification of equation 11.

Rather,

it results from a normalization which must be introduced in
order to account for:

a) the uncertainty regarding the exact

size of the DNA length unit which is being inactivated by a
single inhibitor molecule; b) the distribution of the inhibitor on the specific promoter sites relative to the rest of
the DNA molecule; and c) the fact that the usual expressions
of rb in terms of inhibitor molecules bound per DNA nucleotide, DNA base pair, DNA molecule, and so forth are

p~rely

arbitrary.
As evidenced by the results shown in-Figure 9, introduction of the value of r 1 into equation 11 can, at least
mathematically, compensate for the lack of specific information on these important aspects of the mechanism of
template inactivation.

Therefore, the value of r 1 must be
introduced not only into equation 11, but also into equation

16 as shown by equations 11

Vmax
v

=

KI
1

1 +
1

vmiiX

=

and 16 1

1

,

. -1rb
ri

1 +

1-

rb
rI

( 11 I)

so

Kl
1

v

respectively.

. -1 K1 - K3
Kl

so

( 16 I

)
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One additional test for the necessity of introducing
r 1 into equations 11 and 16 is the fact that for the

= r 1 , equations 11 and 16 yield v = o
and for the case rb = o, the term containing the inhibitor.
limiting case rb

1

1

concentration disappears and equations 11

1

and 16 1 become

identical with the equation for the uninhibited reaction.
v
1
Furthermore, plots of ~ax vs.
for the phenanthridines
rb
1 -

rr

shown in Table 3, also yield straight lines if, and only if,
their corresponding r 1 values shown in Table 3 are introduced into equation 11 (Figures not shown).
1

Equations 11

1

and 16

1

differ only by the factor

which appears in the denominator of equation 16

1

K1 - K3

Kl

•

Accordingly, the two equations remain distinct only if the
value of K3 is not negligible relative to the value of K1 .
For values of K3 which are less than 10% of K1 , equations
11

and 16

1

.

1

may thus appear indistinguishable.

Consequently,

.

among the various mechanisms of inhibition, DEMB (and most
probably by analogy EB, MAPEC and DEMB as well) appear to
act by interfering with the formation of the first productive
enzyme-DNA complex I.
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8.

Alternative Kinetic Methods

In the previous section it was demonstrated that the
reciprocal of RNA polymerase activity depends linearly on
the reciprocal of DNA concentration in the absence of inhibitor or in the presence of a constant ratio of inhibitor
bound per DNA nucleotide (rb).

However alternative kinetic

methods have been extensively used and reported in the
literature.

In these methods the experimental data are

also plotted in the form of the reciprocal of activity vs.
the reciprocal of DNA concentration, but the experiments
are conducted in the presence of either a constant amount
of inhibitor or a constant ratio of inhibitor added per DNA
nucleotide rather than a constant ratio of inhibitor bound
per DNA nucleotide.
In order to determine the suitability of these
alternative kinetic methods for describing quantitatively
the inhibition of RNA polymerase by intercalating drugs,
experiments were conducted under conditions of constant
drug concentration and constant added drug-to-DNA ratio
and the results were presented in double reciprocal plots
of

activity~·

a.

DNA concentration as described below.
Assaying RNA Polymerase in the Presence
of a Constant Ratio of Inhibitor Added
per DNA

Nucleotid~

In the specific case of an inhibitor like ethidium

,

100

[

bromide, DEMB or actinomycin D which were shown to act by
altering the template properties of the DNA, the enzymatic
activity must be assayed with an inhibitor-complexed
template whose composition remains constant, as the parameter under study is varied.

Constant template composition

may readily be achieved experimentally when the template
properties of chromatin for instance, which is a mixture
of DNA template with inhibiting histone proteins, are
being studied (Shih and Bonner, 1970; Cedar and
1973; Keshgegian and Furth, 1972).

Felse~feld,

The high affinity of

the histones for DNA apparently results to an approximately
constant ratio of bound protein per DNA nucleotide as the
concentrations of the DNA and protein components are
increased in a fixed ratio.

However when this method is

adopted for the study of complexes of DNA with compounds
having weaker binding than the histones, as the case is with
EB and DEMB, use of increasing concentrations of a drug-DNA
co~plex

of a given added ratio would result in wide varia-

tions of rb within the range of DNA concentrations assayed
for enzymatic activity.

This point can readily be demon-

strated with the use of equation 5 of section 8 which
allows calculation of the values of rb for any set of DNA
and inhibitor concentrations based on the corresponding
binding constants.
When the

concentration~

of DNA and actinomycin D in

a constant ratio are varied over a ten fold range the values

r
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of rb remain almost unchanged.

On the other hand, variation

of the concentrations of DNA and DEMB over the same range
results in a three fold change in the values of rb due to
the fact that the affinity of DEMB for DNA is approximately
40 times lower than that of actinomycin D.
In order to investigate the relevance of this
observation to the methods of assaying RNA polymerase
activity in the presence of increasing amounts of inhibitorDNA complexes of a constant ratio, the concentrations of
such complexes of DNA with actinomycin D and DEMB were
varied over a ten fold range and assayed for enzymatic
activity.

The results shown in Figure 10 reveal the ex-

pected linear dependence between the reciprocal of
enzymatic activity and the reciprocal of DNA concentration
in the absence of inhibitor and in the presence of a
constant added ratio of actinomycin D.

On the other hand,

severe deviations from linearity occur in the presence of
a constant added ratio of DEMB which, as mentioned, has a
much weaker affinity for the template than actinomycin D.
In the case of DEMB, the values of ;·b change three fold
over the DNA concentration range that was assayed for
activity.

~his

variation in rb produces a template of

altered composition which, therefore, can support RNA synthesis at varying effectiveness.
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Figure 10.

Double reciprocal plots of the rate of

RNA synthesis as a function of template concentration
in the absence of inhibitor, -t-, and in the presence
of a constant ratio of DEMB added per DNA nucleotide
(0.35}, -s-; or a constant ratio of actinomycin D
added per DNA nucleotide (0.00115}, -o-.

Reaction

conditions were identical with those in the legend to
Figure 8.
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b.

Assaying RNA Polymerase in the Presence
of a Constant Amount of Inhibitor

Further demonstration of the effect of template
composition on enzymatic activity can be made by assaying
RNA polymerase at increasing DNA concentrations in the
presence of a constant amount of inhibitor.

In experiments

of this type, the rb of the inhibitor continuously decreases
with increasing concentration of DNA as it can readily be
calculated again with the use of equation 5, section 1 of
Results.

As a result of this gradual

decr~ase

in rb, the

double reciprocal plots shown in Figure 11 exhibit negative
curvilinearity.

The presence of curvilinearity in plots of

this type has been reported previously although the reasons
for this behaviour have not been discussed (Waring, 1965a).
It may parenthetically be noted that the curves of
the double reciprocal plots shown in Figure 11 appear to
converge at the same point of maximum velocity despite the
fact that at least in the case of actinomycin D which is an
inhibitor of the rate of chain elongation, the enzyme may
have not been expected to achieve maximum rate of transcription.

This unexpected behaviour however is apparently due

to the fact that increasingly higher concentrations of DNA
bind increasing amounts of drug and eventually ••dilute" the
inhibitor to the point that inhibitor-free stretches of DNA
are created for the enzyme to use for transcription.
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Figure 11.

Double reciprocal plots of the rate of RNA

synthesis as a function of template concentration in
the absence of inhibitor, -•-, and in the presence of
a constant amount of 15
actinomycin D, -e-.

~~

DEMB, -o-, or 0.0382

~M

Reaction conditions were the same

as those described in the legend to Figuri 8.
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Clearly then, experiments conducted in the presence of
either a fixed added ratio of inhibitor per DNA nucleotide
or in the presence of a constant amount of inhibitor are
inappropriate for describing the properties of the template
for transcription.

Instead, measurements should be carried

out under conditions that produce a template of constant
composition, i.e., at a constant bound inhibitor to DNA
ratio.

Only under such conditions the results would be

informative as to whether a given template inactivator
inhibits RNA synthesis by interfering with the rate terms
of the reaction or the number of sites

tha~

are available

on the DNA for the binding of the enzyme in the manner
described in section 7 of the Results.
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DISCUSSION
The structural analogs of ethidium bromide were found
to be strong inhibitors of RNA synthesis catalyzed by DNAdependent RNA

polymerase~

vitro (sections 1-6 of Results}.

These compounds were shown to bind to the DNA-template and
inhibit RNA synthesis linearly with their template-bound
form within the limits of 10 to 90% inhibition.

The

inhibition of transcription by ethidium bromide and its
structural analogs was then found to be the main result
of a decrease in the number of RNA chains that can

b~

initiated in the presence of inhibitor and, only to a minor
extent, due to a reduction in the rate of elongation of the
product chains (section 5}.

Subsequent examination of the

effect of EB and DEMB, two of the inhibitors under study,
on each step of the process of RNA chain initiation revealed
that the rate constants of RNA polymerase progressing
through these steps are not altered by the presence of
inhibitor although at the same time enzymatic activity is
drastically decreased (section 6}.
Although the use of rifampicin in the elucidation of
the mechanism of initiation was developed with T7 DNA as a
template, initial work on the effect of this inhibitor on
RNA polymerase involved T2 DNA as template and comparable
results were obtained with both templates (Sippel and
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Hartmann, 1971).

Moreover, studies with T4 DNA as templBte
which, as stated in the Introduction, has identical properties with T2 DNA, have shown that the mechanistic features
revealed by the rifampicin method are the same when T4 DNA
is used as template (Hinkle, D.

1971.

Ph.D. Thesis,

University of California, Berkeley, cited by Chamberlin,
1974).
Based on these results, as well as the independent
finding that EB does not inhibit the formation of nonspecific complexes between RNA polymerase and DNA (see
Introduction), it was concluded that EB and DEMB inhibit
either the recognition step or one of the initiation steps
by a mechanism which may not involve an effect of these
compounds on the rate constants of the two initiation steps
(section 6c).

However, in order to identify further the

primary site of inhibition, the effect of DEMB on the
recognition step, i.e., the formation of the first productive
complex I, would have to be studied with respect to the rate
constants and the number of enzyme molecules forming I complexes in the presence and in the absence of inhibitor.
Unfortunately, the formation of the I complex cannot, as
yet, be

stu~ied

directly.

Nevertheless, DEMB was shown not

to affect the rate constants of the other steps of transcription.

Therefore, any method measuring the effect of

the inhibitor on the maximum number and the maximum rate of

r

f
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total product formation may be used to study the effect of
this inhibitor on the formation of the I complex.
As already described in section 8 of the Results,
the published methods for conducting experiments in the
presence of a constant amount of inhibitor or in the
presence of a fixed added ratio of inhibitor per DNA nucleotide are not suitable for describing quantitatively the
properties of the template for transcription.

Instead,

measurements should be carried out under conditions that
produce a template of constant composition; i.e., at a
constant bound inhibitor to DNA ratio.

Only under such

conditions the results would be informative as to whether
a given template inactivator inhibits RNA synthesis by
interfering with the rate terms of the reaction or the
number of sites that are available on the DNA for the binding
of the enzyme.
The results of experiments conducted in the presence
o·f a constant ratio of actinomycin D bound per DNA base
(section 7a) revealed that this drug inhibits the rate of
chain elongation by forming, with the propagating RNA polymerase, ternary ESI complexes which cannot yield further
products causing termination of RNA chain growth.

Howeverr

Hyman and Davidson (1970) have suggested that the decreased
rate of RNA chain growth is due to the fact that actinomycin D slows down the enzyme without forcing it to terminate.

A mechanism of inhibition for actinomycin D, in which

11 1

the transcribing enzyme can continue to synthesize product
beyond an intercalated drug molecule at a reduced rate,
would be kinetically equivalent to a model in which the
ESI complex forms and breaks down to products at a rate
different {slower) than that of the ES complex.

Thus,

if such a mechanism were correct, it would result, as
show~ in Table 4, in smaller values for both Vint and

Kint in disagreement with the experimental data obtained
with actinomycin D {Figure 8).

Of course, the possibility

still remains that K1 = K3 or that either mechanism may
operate depending on the conditions under which RNA polymerase is assayed.

Indeed, according to a proposal by

MUller and Crothers (1968), an elongating enzyme molecule
may proceed past an intercalated actinomycin 0 molecule
only if that molecule dissociates from the template in the
time period required for the addition of the subsequent
nucleotide to the growing chain; if not, the enzyme would
be forced to terminate.

If this model adequately described

the mechanism of inhibition of chain elongation by actinomycin 0, then the enzyme in a ternary ESI complex would
either terminate or slow down depending on the rate of
chain

elong~tion

relative to that of actinomycin 0 dissocia-

tion from the template.

Such rates depend on the temperature,

the ionic strength and the type of the template.

It is

therefore possible that under the conditions of Hyman and
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KCl, r 7 DNA) only a small fraction of RNA
polymerase molecules would terminate when encountering an

Davidson (0.4

~

intercalated actinomycin D molecule while under the assay
conditions of Figure 8 (0.2

~

KCl, T2 DNA) a major fraction
of the transcribing enzyme molecules does so.
The results of the experiments conducted in the
presence of a constant ratio of DEMB bound per DNA nucleotide are discussed below.

I
1
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1.

A Model for the Inhibition of RNA Synthesis
by Structural Analogs of Ethidium Bromide

The derivation of equation 11• in section 7 of the
Results which describes quantitatively the inhibition of
RNA polymerase by EB, DEMB, DMEB and MAPEC was based on
the following assumptions.
1.

Binary complexes between RNA polymerase and

inhibitor (EI) do not form.
2.

RNA polymerase molecules participating in the

formation of the first productive complex (ES) can transcribe without being affected by the presence of inhibitor.
3.

Ternary complexes between the inhibitor (either

free or template-bound) and a productive ES complex do
not form.
4.

Inhibition is the result of the limitations

imposed on the number of ES complexes that can form.

The

inhibitor binds to and distorts the conformation of specific DNA recognition sites to the extent that the enzyme
cannot recognize such sites and form with them the first
productive ES complex.
5.

The inhibitor prevents the formation of the first

productive complex only, i.e., the formation of the recognition complex I.

Inhibition of the formation of a

subsequent complex, e.g., the RS or the OP complexes, would
be equivalent to diverting some of the already formed ES

1 14

complexes into ESI complexes in violation of the previous
assumption (3}.
According to this mechanism, the primary site of
inhibition Ql DEMB,
site for RNA
form of the

~,

MAPEC and DMEB

polymerase~
inhibitor~

~the

recognition

the DNA template, and the active

the intercalated

~molecules

at

the recognition site.

This conclusion is supported by the
results of the experiments conducted with y- 32 P-labelled
nucleotides and rifampicin which demonstrated that neither
the rate of chain elongation nor the rate constants of the
two initiation steps are affected by the presence of the
inhibitors.

The fact that, in the presence of a constant

rb of DEMB, the maximum rate of the reaction remains
identical to that of the uninhibited reaction (Table 4}
indicates that inhibition is the result of a decrease in
the number of chains that can be initiated, not the result
of a decrease in the rate constants governing RNA chain
initiation.

Otherwise, if it were assumed for a moment

that the reason for the observed inhibition is retarded
initiation, then, at infinite template concentration
carrying a given rb of inhibitor, a fraction of the enzyme
would still be retarded and the value of Vmax would appear
to be decreased.
However, a word of caution concerning a possible
misinterpretation of the experimental evidence may be
needed here. , The results of the kinetic experiments in the
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presence of a constant rb of DEMB were interpreted to
indicate that inhibition by this compound is not the result
of a decreased rate of recognition.

Yet, DEMB may indeed

alter the rate of recognition without contributing measurably to the overall inhibition, since the half-life for
recognition

(~20

sec, Chamberlin, 1974} is much shorter

relative to the time of pre-incubation of the enzyme-DNA
complex (7.0 min) as well as the incubation time (7.0 min).
Nevertheless, even if the rate of recognition is slower
in the presence of DEMB, its magnitude is not altered
enough for it to become an important contributor to the
overall inhibition.
Inhibition by EB, DEMB, DMEB and MAPEC is a measure
of the ratio of inhibitor-distorted vs. inhibitor-free
recognition sites which, naturally, depends on the value
of rb of each inhibitor.

Therefore, other factors being

equal, the inhibitory capacity of compounds obeying this
mechanism should only be dependent upon their affinities
for the recognition site en the template.

In other words,

the inhibitory capacity of the template-bound forms of this
class of inhibitors should not vary among the individual
compounds.
Yet, differences were observed among the inhibitory
effectiveness of the intercalated forms of ethidium bromide
and its structural analogs.

Specifically, intercalated

i 16

molecules of EB inhibit RNA synthesis more effectively than
intercalated molecules of DEMB, DMEB, or MAPEC (Table 3).
A reasonable explanation for the observed differences
in the inhibitory effectiveness of the intercalated phenanthridines, which is compatible with the experimental
evidence, is presented below.
a.

The Inhibitory Effectiveness of the DrugDNA Complex may be a Function of its
Dissociation Rate Constants

Every intercalated inhibitor molecule must exist in
a state of dynamic equilibrium with its free form in
solution.

At any concentration of DNA and inhibitor, the

fraction of inhibitor molecules located within the intercalation site-is naturally determined by the magnitude of
the association constant, while the average life-time that
an inhibitor molecule spends in the intercalation site is
determined by the magnitude of the dissociation rate
constant of the template-bound inhibitor.
the

dissoci~tion

In other words,

rate constant, kdiss' of a given inhibitor

will determine, to a large extent, the time period for
which an inhibitor molecule intercalated at the recognition
site will maintain this site distorted (see p. 111 ).
If within this time period, the distorted recognition
site happens to be approached by an enzyme molecule,
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recognition will not take place and a productive complex
will not form.

If, on the other hand, the inhibitor

happens to dissociate at a time when an enzyme molecule is
in the vicinity of the recognition site and within a
distance permitting formation of the I complex, the inhibitor will be "substituted" by the enzyme on the recognition site.

This is expected, because the latter has a much

higher affinity for the template (5-6 orders of magnitude)
than the inhibitor--mainly due to a kdiss of the inhibitor
8-10 orders of magnitude smaller than the kd.lSS of the
enzyme (Bresloff and Crothers, 1975; Chamberlin, 1974).
Thus, intercalated inhibitor molecules which dissociate
more slowly from the template would be stronger inhibitors
of RNA synthesis since the enzyme is given less time for
forming a productive complex at a site unoccupied by
inhibitor.

Therefore, the order of inhibitory effectiveness

of the template-bound forms of compounds like EB, MAPEC,
DEMB and DMEB which follow the mechanism of inhibition of
RNA synthesis described quantitatively by equation 11',
should be inversely related to the magnitude of their
dissociation rate constants.
For any of these inhibitors and at any rb below ri'
two kinds of recognition sites exist in solution:

a)

inhibitor-free sites on which the enzyme can form productive complexes at its normal rate and b) inhibitor-carrying

1 18

sites which the enzyme cannot recognize except during the
time the inhibitor momentarily dissociates from them.

The

inhibitor-free and the inhibitor-carrying sites are of
course in dynamic equilibrium with one another (as well as
with the rest of the DNA molecule) via the free form of
the inhibitor and their relative population would be determined by the value of rb.
When RNA polymerase is mixed with DNA at 0°C and then
is incubated at 30°C for increasing periods of time before
being assayed for RNA synthesis, a sharp increase in
enzymatic activity at short pre-incubation times is observed
followed by a much slower rise in activity at longer preincubation times (see section 6b of Results).

This biphasic

dependence of enzymatic activity on pre-incubation time may
be interpreted as follows:

The early sharp rise in activity

may be associated with the formation of the recognition I
complex on inhibitor-free sites and the much slower rise
in activity may be attributed to the slow ''displacement"
of the inhibitor by the enzyme from the inhibitor-carrying
recognition sites.

The same interpretation could also be

given to the biphasic character of the curves describing
the formation of the cellulose-nitrate non-filterable
complex reported by Richardson (1973a).
According to this explanation, the displacement rate
of the inhibitor from the DNA recognition site by RNA

11 9

polymerase would be of the order of several minutes.
However, the two reactions determining the rate of displacement, i.e., the dissociation of the inhibitor from
the DNA and the rate of recognition, are much faster
2
processes {k dissociation -- 10 s -l for EB ; Bres 1 off and

Crothers, 1975; t 112 recognition ~ 20 sec, Chamberlin,
1974). Therefore, the rate of displacement should be a
much faster process, having a half-life of the same order
of magnitude as the recognition reaction.

If, however,

a recognition site is inactivated only when more than one
inhibitor molecules are present, then, the period of time
for which such a site would remain inhibitor-free, i.e.,
available for recognition, would be much smaller.

In this

case, the rate of substitution could easily be of the order
of several minutes.

In fact, the results shown in Figure

4 provide some indication that more than one inhibitor
molecules are
At·

l~ast

req~it·ed

for inactivating a recognition site.

in the case of DEMB and DMEB, inhibition is not

observed until approximately one inhibitor molecule is
bound per 17 base pairs, a value close to the estimated
size ("-'20 base pairs;

Heyden~~.,

1975) of the recogni-

tion site, while total inhibition is observed at an rb of
0.08 which corresponds to approximately three inhibitor
molecules bound per recognition site.
As mentioned previously, the order of inhibitory
effectiveness of the template-bound forms of EB, DEMB, DMEB
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MAPEC should be inversely related to their dissociation
rate constants.

These parameters, though, have not been

measured for the structural analogs of EB.

Nevertheless,

the magnitudes of the dissociation rate constants have been
measured for the intercalated form of proflavine, another
inhibitor of RNA synthesis which forms with DNA similar
complexes like those of ethidium bromide.

It was found

that the magnitude of the dissociation rate constant of
intercalated proflavine decreases as the temperature .of
the environment is decreased and as the ionic strength is
increased {Li and Crothers, 1969).

Accordingly, if the

inhibitory effectiveness of the template-bound form of
proflavine were indeed a function of the dissociation rate
constant of its DNA complex, then, intercalated proflavine
should be a stronger inhibitor at lower temperature and
higher ionic strength.

The inhibitory strength of template-

bound proflavine has not been determined as a function of
these two parameters.

However, the intercalated form of

ethidium bromide is indeed found to be a more effective
inhibitor at lower temperatures and higher ionic strengths
(Richardson and Parker, 1973).

Due to the similarities of

the DNA complexes of the two drugs, it may be assumed that
the dependence of the kdiss of the DNA-EB complex on ionic
strength and temperature most probably parallels that of
the proflavine-DNA complex.

Therefore, the fact that the
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template-bound form of EB is found to be a more effective
inhibitor at low temperatures and higher ionic strengths,
i!e., under conditions favoring slower dissociation of the
drug-DNA complex, is consistent with the idea that the
inhibitory effectiveness of the intercalated phenanthridines is a function of the magnitude of the dissociation
rate constant of their template-bound forms.
However, due to the indirect nature of the evidence
discussed above, alternative explanations for the observed
differences in the inhibitory effectiveness of the templatebound phenanthridines must be considered.
A serious obstacle in the quantitative treatment of
the system under study has been the lack of information
concerning the exact stoichiometry between the inhibitor
and the template, i.e., how many inhibitor molecules
inactivate how much of the template.

Related to this

problem, also, are the lack of information concerning the
exact nature of the DNA structural features involved in
enzyme recognition, as well as the possibility that the
structural analogs of EB possess some degree of preference
(binding specificity) for interaction only with certain
types of DNA bases.

Thus, if the inhibitors under

comparison exhibited binding specificity, a direct comparison of the inhibitory effectiveness of their bound
forms would not be possible on the basis of plots of

ft
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'

activity~·

rb of the type shown in Figure 4, since the

relationship rb

=

rb would not necessarily hold true

(rb is the ratio of inhibitor bound per recognition site
as opposed to rb, the ratio of inhibitor bound per deoxynucleotide).

One, then, might postulate that the observed

differences in the inhibitory effectiveness of the bound
analogs of ethidium bromide are due to differences in their
bfnding specificities for the template.
This possibility, however, seems unlikely since at
least ethidium bromide exhibits no preference for promoter
sites on DNA molecules (Giacomoni

~ ~·,

1974).

The bind-

ing constants and the maximum number of binding sites for
ethidium bromide of DNA molecules having base compositions
varying between 35% and 72% in G + C content have been
found to be almost identical and the small differences
observed do not correlate to the G + C content of the DNA
(Waring, 1965b).

These results have, since, been inter-

preted to indicate lack of binding specificity for ethidium
bromide.

No evidence for binding specificity on the part

of the analogs of ethidium bromide is available, except
for the linearity of the Scatchard plots (Figure 1;
Kindelis, 1976) which may be interpreted to indicate lack
of significant binding preference for these compounds.
The situation, however, appears to be different in complexes of ethidium bromide with dinucleotides, in which
ethidium bromide exhibits some preference for interaction
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with pyrimidine-purine sequence isomers (Krugh et al., 1975).
Yet, the results of binding specificity or conformation
studies of EB dinucleotide complexes may not be representative of the properties of the DNA ethidium bromide complex
(Tsai et

~.,

1975}.

A second possible explanation for the observed
differences in the inhibitory effectiveness among the bound
forms of the structural analogs of ethidium bromide must be
considered.

One might be tempted to explain this phenomenon

by a mechanism in which intercalation of one (or more) EB
molecules distorts the conformation of a recognition site
to a larger extent than DEMB so that, in the latter case,
some degree of recognition with subsequent for-mation of
productive complexes may take place.

Alternatively, one

might postulate that the presence of the bulkier phenyl
group on the intercalated phenanthridinium ring of EB
interferes with recognition more effectively than the smaller
substituents on DEMB.

Both of these mechanisms, however,

should require partial recognition by the enzyme of a DNA
site carrying one (or more) inhibitor molecules; i.e., a
process equivalent to assuming formation of ternary ESI
complexes.

Such a mechanism would be in disagreement with

the mechanism of inhibition by DEMB if the latter would
occur through the inhibition of the formation of an ESI
complex.

Had the formation of a ternary complex been
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responsible for the observed inhibition, the kinetic
pattern in the presence of a constant rb of DEMB would
resemble that of actinomycin D, in contradiction with
the experimental findings.

Therefore, although partial

recognition by RNA polymerase of inhibitor-distorted
sites on the DNA does probably take place, either its extent and/or its duration is presumably such that it does
not constitute a major contribution to the overall inhibition by compounds of the same kinetic behavior as DEMB.
b.

The Magnitude of the Dissociation Rate
Constants May Distinguish Inhibitors of
Chain Initiation from Inhibitors of
Chain Elongation

A comparison of the dissociation rate constants of
actinomycin D, proflavine and EB reveals that the dissociation rate constant of the ''pure" elongation inhibitor
actinomycin D is at least 3-4 orders of magnitude slower
than that of proflavine (Li and Crothers, 1969; MUller and
Crothers, 1968}.

The latter inhibits RNA chain initiation

to the same extent as RNA chain elongation (Maitra et
1967).

!l·•

In turn, the dissociation rate constant for

proflavine is half an order of magnitude lower than the
dissociation rate constant for EB which inhibits RNA chain
elongation to a smaller degree than proflavine (Bresloff
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and Crothers, 1975).

It thus appears that intercalators

having small dissociation rate constants inhibit perhaps
mainly RNA chain elongation (covalently bound intercalators
would be the extreme class of elongation inhibitors).

On

the other hand, compounds having high dissociation rate
constants from the template inhibit mainly RNA chain
initiation.

This differentiating effect of the magnitude

of the dissociation rate constants on the mechanism of
inhibition of RNA synthesis by DNA intercalators could
perhaps be the result of two factors:

a) the different

mechanisms of chain recognition and chain elongation by
RNA polymerase and b) the small target size of the recognition site

{~V20

base pairs; Heyden et .!]_., 1975) relative

to the size of the "elongation site" (up to 10,000 base
pairs; Bremer, 1970).

Because of these two factors a

slowly dissociating intercalator at low values of rb would
inhibit elongation.

Under these conditions the majority

of the recognition sites would remain inhibitor-free due
to their small target size and, therefore, initiation would
not be inhibited.

In contrast, a fast dissociating inter-

calator at low values of rb would not affect elongation
despite the. fact that the elongation site would be loaded
with inhibitor molecules.

Also, at first, initiation would

not be inhibited because of the small target size of the
recognition site.

In the latter system at higher values of

r

''

126

rb, however, the recognition sites would be loaded with
inhibitor molecules and the overall inhibition of RNA
synthesis would parallel the inhibition of initiation.
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2.

The Molecular Basis of the Trypanocidal
Activity of the Phenanthridines

It has been postulated that the trypanocidal activity
of various phenanthridinium compounds resides in the capacity
of these compounds to intercalate into the DNA templates and,
as a result, interfere with the biological functions and/or
the metabolism of these macromolecules {Waring, 1970).
In an attempt to determine the effect of the phenanthridines on particular functions of the DNA molecule·and
possibly identify the primary target of their pharmacological action, the inhibitory effectiveness of a number of
phenanthridines against enzymes utilizing DNA as template
or substrate was compared with the trypanocidal activity of
these compounds (Kindelis, 1976}.

The results obtained

with DNA polymerase I and pancreatic deoxyribonuclease
suggested that the pharmacological action of the structural
analogs of ethidium bromide may not parallel their effectiveness as inhibitors of these enzymes in vitro (Kindelis, 1976).
Therefore, the property of the structural analogs of EB to
inhibit strongly at least one enzyme catalyzing DNA repair
and one enzyme catalyzing DNA degradation does not appear to
be directly related to the pharmacological action of these
compounds.
In contrast, with the exception of DMNt, the order but
not the magnitude of inhibition of RNA synthesis by a number

128

of structural analogs of EB is found to parallel their
trypanocidal activity (Table 2).

Consequently, the

pharmacological activity of the phenanthridines appears
to be directly related to the ability of these drugs to
inhibit transcription by impairing the template properties
of the DNA.

According to the evidence discussed pre-

viously, one could propose that the capacity of at least
some of the structural analogs of EB for template inactivation may be determined by the magnitude of the dissociation
rate constants of their DNA complexes.

According to this

hypothesis, the variation in trypanocidal activity among
these drugs could in turn be a function of the variation
in the magnitude of the dissociation rate constants among
the various phenanthridinium derivatives.
In the recent past substantial efforts have been
directed at elucidating a possible relationship between
the affinity for DNA of compounds believed to act by
associating with this macromolecule and the carcinostatic
properties of these compounds (Le Pecq

~

!!·•

1974).

Some studies have also entertained the possibility of a
close relationship between the extent of conformational
distortion of the double helix upon drug binding and drug
action (Wakelin and Waring, 1974).

However, in view of

the present findings with the structural analogs of ethidium
bromide and actinomycin 0, attention should be called to one

129

additional parameter, namely the dissociation rate constants
of the drug-DNA complex, which might also play an important
regulatory role in drug action.

At least in the case of

inhibition of transcription by intercalating compounds this
parameter might turn out to be the factor that determines not
only whether a given drug causes inhibition of RNA chain
elongation or initiation but also, which one, among inhibitors having identical mechanisms of action, will exert the
strongest overall effect on RNA synthesis.
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SUMMARY
The mechanism of inhibition of DNA-dependent RNA
polymerase of

I· coli K-12 by structural analogs of ethid-

ium bromide has been investigated in an in vitro system
utilizing T2 DNA as template.
Ethidium bromide analogs carrying large hydrophobic
groups at position

! of the phenanthridinium ring system

are the strongest inhibitors of RNA synthesis.
All of the compounds examined appear to inhibit RNA
synthesis as a result of their affinity for DNA by inactivating template molecules rather than enzyme molecules.

The

concentration of DNA-template bound drug, which is the active
form of the inhibitor, is found directly related to the
degree of inhibition of RNA polymerase.

Furthermore,

identical amounts of various template-bound inhibitors effec.t
inhibition to different extents.

These differences may be

attributed to the individual structural characteristics of
these drugs.
Measurements of the simultaneous incorporation of [ 3 H]uridine triphosphate and y-[ 32 P]-adenosine and guanosine
triphosphates revealed that phenanthridines inhibit mainly
the initiation step of RNA synthesis with very little or no
effect on the process of RNA chain elongation.

It thus

appears that ethidium bromide and its analogs inhibit
differentially one or more of the steps recognized in RNA
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chain initiation.

Inhibition by these compounds might be

the result of interference with the number of enzyme
molecules attached to initiation sites or with the rate at
which these molecules can initiate the synthesis of an
RNA chain.

Both mechanisms may also be involved.

To test

these alternatives, the rate and the number of enzyme
molecules that proceed through individual initiation steps
were measured in the presence and in the absence of inhibitor.

The inhibitor was found to have no effect on the rates

of either one of the initiation steps.

The number of enzyme

molecules that are proceeding through these steps, in the
presence of ethidium bromide or its analogs was, however,
dramatically reduced.
The reduction in the number of enzyme molecules which
are able to proceed through the initiation events may be
attributed either to an interference with the formation of
the first recognition complex or to a decrease in the number
of productive complexes that can form subsequent to recognition.

These two alternatives were distinguished by deter-

mining the dependence of enzymatic activity on template
concentration in the presence of a constant ratio of bound
inhibitor to the DNA-template.

The results are in good

agreement with the theoretically predicted behaviour of
inhibitors which act by preventing enzyme recognition of
template binding sites.

Such sites are apparently distorted

as a result of intercalation of the drug.
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The data also indicate that displacement of the
inhibitor from the recognition site by direct interaction
between RNA polymerase and the inhibitor-''recognition" site
complex does not take place.

Consequently, it appears that

the enzyme may be able to recognize and bind productively
and irreversibly only to recognition sites which are
momentarily free of inhibitor.

Therefore, the differential

inhibitory effectiveness of the DNA complexes formed with
structural analogs of ethidium bromide may be related ·to
differences among the dissociation rate constants of these
complexes.
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APPENDIX
I.

II.

Explanation of Symbols

s

DNA

(so)

Total DNA concentration

(s)

"Inhibitor-free" DNA concentration

I

Inhibitor

(i)

"Free" inhibitor concentration

(si)

DNA-inhibitor complex concentration,
i.e. bound inhibitor concentration

E

Inhibitor bound per DNA nucleotide
(molar ratio)
Enzyme

(eo)

Total enzyme concentration

(e)

"Free" enzyme concentration

(es)

Enzyme-DNA complex concentration

(esi)

Enzyme-DNA-inhibitor complex concentration

K' 1

Enzyme-DNA dissociation constant

KI

Apparent DNA-inhibitor association constant

The Relationship
Between (s) and
(s 0 )
-

For an inhibitor interacting with a DNA site according
to the expression

S

I ,

+

SI

the following relationship may be derived:
(s)

=

(s ) 0

(si)

(s)

(so)

~= 1 (so)

rb

(s) == (1-rb)(s 0

)

(1)
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III. Kinetics of Template Inactivation
a.

Kinetic Scheme:

j
E

[

s

I

~s~
~ ESI~
.<

I

SI

~

p

7

_:Assumptions:

b.

1.

ES does form and does yield product

2.

SI does form

3.

EI does not form

4.

ESI does form and does yield product

5.

On the time scale of the experiments described
in this Thesis all steps are rapidly reversible
with the exception of the formation of p from
ES (or ESI).

6.

Reinitiation does not alter significantly the
rate of the reaction.
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c.

Equations

The following equilibrium expressions may be
written to describe the reactions taking place under
the scheme shown in Section Ilia of the Appendix.
E

0

=E

+ ES + ESI
(e

0

=

(e)
E + S

=

)

ES + I

0

)

-

(es) - (esi)

(2)

= K1 (e)(s) =

K {(e 0 )-(es)-(esi)}(s)
1

(3)

= SI
(si)

E + SI

(e

= ES
(es)

S + I

(e) + (es) + (esi)

=

(4)

K1 (s)(i)

=

ESI
(esi) = K3 (e)(si)

=

=

K {(e )-(es)-(esi)}(s)
0
3

(5)

ESI

(esi)

=

K4 (es)(i)

(6)
(7)
(8)

d.

Derivations

Based on the general kinetic scheme shown in
Section lila of the Appendix, the expressions for the
ES and the ESI complexes are obtained as shown below.
These expressions are subsequently used in deriving
the equations describing each particular mechanism
of inhibition.
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In order to obtain an expression for (es),
equation (6) is substituted into equation (3):
(es)

= K1 (s)(e 0 )

-

K1 (s)(es) - K1 K4 (s)(es)(i)

(es){1 + K (s) + K K (s)(i)}
1
1 4
(es)

= K1 (e 0 )(s)

K (e )(s)
1 0

=

Using equation (8), the above expression can be
transformed to:

(es)

=

(9)

In order to obtain an expression for (esi),
the expression for (es) from equation (6) is substituted into equation (5):

(esi)

(esi) {1 +

(esi)

=
1 +

=
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Using equation (8), the above expression can be
transformed to:

=

(esi)

1.

(10)

Binding Site Inactivation
pescription:
It is assumed that ternary
ESI complexes do not form. Therefore,
K =o.
Only binary ES complexes yield
3

product.

=

Therefore, V

max
the rate expression becomes
v

=

k(e

0

)

and

k(es)

Using equation (9), the general expression
for (es), the above expression can be transformed to:

v

=

k(e )•K (s)
1
0
1 + K (s) + K (si)
1
3

but it i.s assumed here that K :::o.
3
v

Therefore,

vmax(s)

=
+ ( s)

K'

1

+ (s)

Substituting the expression for (s) from
equation (1):

v =

Vmax (1-rb)(s o )
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1

1

=

v

K' 1
--.

=

v

1

+

K' 1

. -1 -

1

vmax

Vmax

vmax

2.

+

(1-rb)

(so)

. -1 -

(1-rb)

(11)

(12)

(so)

"Rate" Inhibition
Description:
It is assumed that ternary
ESI complexes form but do not yield
product. The affinity of E for S is as
strong as the affinity of E for SI;
therefore, K =K . Only the ES complex
1 3
can form product. Therefore, V
= k(e o ),
max
and the rate expression becomes
v

=

k(es)

Using equation (9), the general expression
for (es), the above expression can be transformed to:

v

=

1 + K1 (s) + K (si)
3

=

Substituting the expression for (s) from
equation (1):

v

=

K3

+ (s) + -(si)
K1
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Vmax (1-rb)

=

v

but, it is assumed here that K =K .
3 1

=

v

Vmax (1-rb)
1

V

=

max ( 1-rb)(s o )

+

. 1

1

Therefore,

=

+

K' 1

1
.__,_

(13)

v

Vmax

=

v

3.

. -1

1

+

(14)

(s )
0

Mixed Binding §ite Inactivation
D<~script

ion:

It is assumed that ternary

ESI complexes form and yield product at
the same rate as the ES complexes, but the
affinity of E for S is different than the
affinity of E for SI. Therefore, K f K ,
3
1
Vmax = k(e o ) and the
· rate expression
becomes
v

=

k(es + esi)
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Using equations (9) and (10), the general
expressions for (es) and (esi), the rate
expression becomes

v =

v

=

k{K

(e )(s) + K (e )(si)}
3 0
1 0
1 + K (s) + K3 (si)
1

V
{K (s) + K (si)}
3
max 1

Substituting the expression for (s) from
equation (1):

=

v

Vmax{K 1 (1-rb)(s 0
1 + K1 (1-rb)(s 0

)

)

+ K3 (si)}
+ K3 (si)

and dividing by (s ):
0

=

v

Vmax{K1( 1 -rb) +K3•rb}
1
---- + K1 (1-r ) + K3 ·rb
(s )
b
0

=

v

Vmax{K1 - rb(K1-K3)}(so)
1 + {K1 -rb(K1 -K 3 )}(s 0

1

v

Vrna::·:
v

1

=

1

1

---- + -----------------·----

1
1

(15)

Vmax {K 1 +rb(K
. 3 -K 1 )} (s o )

vmax

=

}

+

1
(16)
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4.

Mixed Inhibition
Description:
It is assumed that ternary
ESI complexes form and yield product at
a different rate than binary ES complexes,
but the affinity of E for S is different
than the affinity of E for SI. Therefore,
K
K and the rate expression becomes
1
3

r

v

= k(es)

+ k(esi)

Using equations (9) and (10), the general
expressions for (es) and (esi), the above
equation becomes:

v

=

k•K (e )(s) + k·K (e )(si)
1 0
3 0
1 + K (s) + K (si)
1
3

Substituting the expression for (s) from
equation (1):

v =

(e 0 ){k·K 1 (1-rb)(s
0

)

1 + K1 (1-rb)(s
0

)

+ k•K 3 (si)}
+ K3 (si)

Dividing by (s 0 )·•

v

=

v

=

{Vmax·K1( 1 -rb) + V~ax·K3•rb}(so)
1 + {K1 (1-rb) + K3 •rb}(s
0

)
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1

v

=

+

K1 (1-rb) + K3•rb
Vmax •K1 (1-r b ) + V'max •K 3 •r b
1
1
(17)
Vmax •K1 ( 1-rb ) + V'max •K 3 •r b (so)

·--
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IV.
a.

Data for some figures
Data for Figure 1.

If

DNA
(m~!)

rb

A460

4

(Mxl0 )

If

(mH)

rb

A460
DEMB

EB

satd
0.945
0.578
0.399
0.263
0.137
0.074

0.420
0.478
0.513
0.550
0.610
0.725
0.823
1. 003

0.0171
0.0274
0.0383
0.0560
0.0899
0.1188
0.1719
isosbestic points at: 390,
512 nm

0.0164
0.025
0.033
0.044
0.060
0.072

satd

0.390

0.578
0.399
0.263
0.137
0.074

0.528 0.0225
0.573 0.0285
0.631 0.035:~
0.721 0.0439
0.784 0.0504
0.886
383, 496 nm

MAPEC

satd
0.840
0.525
0.347
0.221
0.137
0.074

0.612
0.702
0.749
0.802
0.866
0.931
1. 000
1.104

(_!ix10 4 )

DMEB

satd
0.0198
0.0280
0.0361
0.0447
0.0525
0.0586

0.0373
0.0567
0.0787
0.1052
0.1321
0.1607
0.2038
isosbestic points at: 370,
460 nm

0.0501
0.0664
0.0875
0.1201
0.1430
0.1800

0.840
0.525
0.347
0.221
0.137
0.074

0.485
0.560 0.0209
0.601 0.0297
0.647 0.0386
0.703 0.0486
0.764 0.0572
0.825 0.0667
0.928
380, 49 2 nm

0.0357
0.0552
0.0772
0.1038
0.1329
0.1619
0 . 2110

150

b.

Data for Figure 2.

DNA
mM

cpm

DNA
mM

no inhibitor
0.010
0.016
0.026
0.044

+

11130
15817
19648
26079

+

2615
4490
6121
.6912
9710
+

10,416
9,935
19,480
18,529
30 '39 7
31,448
51,634
43, '767

DEMB

0.016
0.026
0.036
0. 0 so
0.072

MAPEC

0.016
0.016
0.026
0.026
0.036
0.036
0.056
0.056

cpm

0.016
0.026
0.036
0.050
0.072

DMEB
736
1420
2185
2667
5131

Plotted values for DEMB and DMEB have been multiplied
by 12.5 and for the uninhibited reaction by 2.78 in order
to normalize the various specific activities of XTP used
in each reaction.
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c.

Data for Figure 3a.

I
(lJ~!)

I

activity, (%)

(lJ~)

EB
2.39
4.78
7.16
7.96
9.55
11.14
15.12
27.06

82.5
59.2
40.5
25.8
21.9
10.9
4.5
0.0

98.6
82.2
74.8
53.6
38.2
29. 7
19.6
11.5
0.0

a

DEMB
4.6
3.8
3.8
0.2
3.6
1.8
0.4

6.65
11.64
14.97
18.29
23.28
28.27
44.90
56.54

MAPEC
5.24
6.98
8.73
10.48
12.22
13.97
15.71
19.21
59.56

activity, (%)

91.7
74.4
60.3
42.5
22.3
11.6
2.0
0.0

6.7
6.6
6.4
4.8
. 2. 4
0.0
0.0

DMEB
1.6
4.2
2.1
2.6
5.8
3.5
1.5
1.1

5.95
10.41
13.38
17.84
20. 81
26.77
50.56

94.2
79.9
60.0
33.5
20.5
9.9
0.0

7.8
6.5
6.0
3.8
2.6
0.4
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d.

Data for Figure 3b.

I
(l-1~!)

activity,
(%)

I
(l-IM)

DMNC
1.1
1.8
2.3
2.3
3.0
3 5
4.0
5.3
7.1
8.8
8.8
9. 5
10.7
13.0
15.0
18.0
30.0
0

97.8
92.0
83.0
75.0
81.5
89.0
74.5
68.5
12.5
9.0
12.0
51.0
18.5
8.0
6.0
1.5
0.0

activity,
(%)

I
( l-1~!)

DDEB

MAPAC
2 2
4.4
6.8
9.0
9.0
11.4
12.5
13.6
17.0
21.0
28.7
48.2
0

95.0
86.0
79.5
70.0
78.0
62.0
52.0
46.5
37.0
24.5
12.0
2.0

activity,
(%)

2 2
5.0
9.0
9.0
12.4
12.4
17.0
21.0
29.0
48.0
52.4
0

95.0
92~0

80.0
83.0
65.0
60 5
44.5
27.5
14.5
4.0
2.0
0

153
e.

Data for Figure 5.

I
(~M)

activity, (%)
A starters

a

activity, (%)
G starters

a

EB
2.39
4.78
7.16
7.96
9.55
11.14
15.12
27.06

103.0
79.7
60.1
47.1

11.8
7.1
12.6
5. 7

28.7

8.9

0.0

89.1
60.9
49.4

10.9
8.0
13.8

17.2

9.1

5.3
0.0

0.7

66.3
51.8
40.3
31.7
13.7
4.9
0.0

10.5
11.3
11.2
9.8
4.0
2.0

58.7

15.2

36.4

9.9

9.5

3.0

1.4
0.0

1.0

DEMB
6.65
11.64
14.97
18.29
23.28
28.27
56.54

1."2
5. 5
11.3
13.9
4.0

97.5
103.1
72.0
40.6
30. 5
0.0

MAPEC
5.24
6.98
8.73
10.48
12.22
LL97
15.71
19.21
59.56

110.0

9.5

76.8

3.0

52.0

3.5

33.0
0.0

Continued on following page.

2.1

154

e.

Data for Figure 5 (continued)

I

(llM)

activity, (%)
A starters

a

activity, (%)
G starters

a

DMEB
5.95
10.41
13.38
17.84
20.81
26.77
50.56

103.9
85.6
65.0
39. 2
28.7
0.0

11.9
14.0
7.4
8. 5
2.3

67.9
63.3
45.2
22.3
10.8
1.5
0.0

5.9
11.8
15.6
9.9
4.9
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Data for Figure 5 (continued)

[3H],

(%)
[32P], (%)

I
( M)

EB
2.4
4.5
7.0
7. 5
9.5
10.0
10.5
11.5
12.5
13.5
15.0
18.0
21.0
23.5

MAPEC

DEMB

DMEB

0.95
0.80
0.78
0.96
0.70
0.90
1. 00
0.85
0.85
0.97
0.80

0.90
0.90
0.85

0.95
0.85

156

f.

DNA
ll~

Data for Figure 8.

I
llM

10
10
10
16
16
16
26
26
26
44
44
44

cpm
10410
10764
12215
14030
17218
16203
19690
19587
19667
26438
25918
25880

cpm

(J

11130

956

15817

1629

19648

54

26079

312

3252

117

5479

386

7694

1032

10132

175

3287

25

5059

774

7461

1656

11605
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Act. D
8
8
8
12
12
12
20
20
20
34
34.
34

0.0153
0.0153
0.0153
0.0193
0.0193
0.0193
0.0273
0.0273
0.0273
0.0413
0.0413
0.0413

3357
3125
3273
5541
5831
5066
6805
7450
8826
10009
10056
10333

DEMB
8
8

8
12
12
12
20
20
20
34
34
34

16.82
16.82
16.82
17.04
17.04
17.04
17.48
17.48
17.48
18.25
18.25
18.25

3270
3305
5557
5453
4167
7293
5895
9195
11665
11756
11393\
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